| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 697 | 2024 | 5181 | 52.720 |
Why?
|
| Boronic Acids | 159 | 2015 | 965 | 17.660 |
Why?
|
| Pyrazines | 160 | 2015 | 1230 | 15.840 |
Why?
|
| Thalidomide | 118 | 2022 | 890 | 13.410 |
Why?
|
| Antineoplastic Agents | 229 | 2024 | 13695 | 8.700 |
Why?
|
| Protease Inhibitors | 55 | 2020 | 791 | 7.490 |
Why?
|
| Dexamethasone | 98 | 2023 | 1951 | 7.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 148 | 2023 | 11524 | 6.420 |
Why?
|
| Bone Marrow | 63 | 2021 | 2948 | 5.230 |
Why?
|
| B-Cell Maturation Antigen | 17 | 2024 | 140 | 4.780 |
Why?
|
| Apoptosis | 146 | 2023 | 9727 | 4.600 |
Why?
|
| Proteasome Endopeptidase Complex | 53 | 2023 | 1338 | 4.220 |
Why?
|
| Drug Resistance, Neoplasm | 86 | 2023 | 5172 | 4.040 |
Why?
|
| Histone Deacetylase Inhibitors | 26 | 2020 | 789 | 3.730 |
Why?
|
| Waldenstrom Macroglobulinemia | 44 | 2023 | 1052 | 3.500 |
Why?
|
| Periodicals as Topic | 10 | 2022 | 1432 | 3.370 |
Why?
|
| Cell Line, Tumor | 166 | 2024 | 16689 | 3.220 |
Why?
|
| Bone Marrow Cells | 52 | 2021 | 2513 | 3.190 |
Why?
|
| Stem Cell Transplantation | 33 | 2022 | 1620 | 3.040 |
Why?
|
| Tumor Cells, Cultured | 89 | 2021 | 6314 | 3.020 |
Why?
|
| Osteoclasts | 17 | 2018 | 729 | 3.000 |
Why?
|
| Mice, SCID | 82 | 2021 | 2716 | 2.960 |
Why?
|
| Antibodies, Monoclonal | 51 | 2021 | 9274 | 2.890 |
Why?
|
| Plasma Cells | 24 | 2022 | 591 | 2.830 |
Why?
|
| T-Lymphocytes, Cytotoxic | 13 | 2024 | 1821 | 2.650 |
Why?
|
| Gene Expression Regulation, Neoplastic | 75 | 2023 | 8428 | 2.650 |
Why?
|
| Immunologic Factors | 29 | 2023 | 1580 | 2.640 |
Why?
|
| NF-kappa B | 44 | 2023 | 2499 | 2.620 |
Why?
|
| Xenograft Model Antitumor Assays | 62 | 2020 | 3557 | 2.580 |
Why?
|
| Humans | 821 | 2024 | 744343 | 2.480 |
Why?
|
| Stromal Cells | 44 | 2017 | 1355 | 2.380 |
Why?
|
| Drug Synergism | 44 | 2020 | 1792 | 2.370 |
Why?
|
| Interleukin-6 | 59 | 2019 | 3200 | 2.360 |
Why?
|
| Cell Proliferation | 89 | 2023 | 10481 | 2.270 |
Why?
|
| Salvage Therapy | 23 | 2021 | 1275 | 2.210 |
Why?
|
| Melphalan | 25 | 2023 | 431 | 2.150 |
Why?
|
| Signal Transduction | 95 | 2021 | 23403 | 2.100 |
Why?
|
| Neoplasm Proteins | 26 | 2022 | 3703 | 2.070 |
Why?
|
| Enzyme Inhibitors | 38 | 2018 | 3798 | 2.060 |
Why?
|
| Imidazoles | 19 | 2015 | 1206 | 2.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 48 | 2023 | 5442 | 1.950 |
Why?
|
| Immunotherapy | 29 | 2022 | 4445 | 1.930 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 12 | 2021 | 177 | 1.900 |
Why?
|
| Bone Density Conservation Agents | 10 | 2018 | 773 | 1.900 |
Why?
|
| Cell Survival | 64 | 2019 | 5882 | 1.860 |
Why?
|
| Angiogenesis Inhibitors | 26 | 2021 | 2038 | 1.830 |
Why?
|
| Molecular Targeted Therapy | 21 | 2021 | 2727 | 1.820 |
Why?
|
| Caspases | 29 | 2020 | 928 | 1.820 |
Why?
|
| HSP90 Heat-Shock Proteins | 16 | 2015 | 434 | 1.790 |
Why?
|
| Tumor Microenvironment | 32 | 2023 | 3586 | 1.790 |
Why?
|
| Dendritic Cells | 19 | 2023 | 2725 | 1.790 |
Why?
|
| Lactones | 8 | 2016 | 329 | 1.770 |
Why?
|
| Phosphorylcholine | 13 | 2012 | 162 | 1.760 |
Why?
|
| Immunoconjugates | 9 | 2021 | 901 | 1.760 |
Why?
|
| Oligopeptides | 16 | 2020 | 1189 | 1.750 |
Why?
|
| Recurrence | 67 | 2020 | 8340 | 1.730 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 13 | 2021 | 2915 | 1.730 |
Why?
|
| Killer Cells, Natural | 18 | 2024 | 2133 | 1.720 |
Why?
|
| Neoplasm Recurrence, Local | 30 | 2023 | 9239 | 1.720 |
Why?
|
| Hydroxamic Acids | 17 | 2017 | 494 | 1.680 |
Why?
|
| Cell Adhesion | 39 | 2016 | 3144 | 1.670 |
Why?
|
| Cell Communication | 14 | 2020 | 1621 | 1.640 |
Why?
|
| Pyrroles | 12 | 2020 | 1146 | 1.580 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 4 | 2018 | 86 | 1.570 |
Why?
|
| Neoplasms | 38 | 2021 | 21683 | 1.570 |
Why?
|
| Neoplasm, Residual | 11 | 2023 | 973 | 1.570 |
Why?
|
| Proto-Oncogene Proteins c-akt | 26 | 2014 | 2503 | 1.520 |
Why?
|
| Diphosphonates | 10 | 2015 | 623 | 1.510 |
Why?
|
| Clinical Trials as Topic | 56 | 2018 | 7913 | 1.500 |
Why?
|
| Bone Diseases | 8 | 2018 | 416 | 1.420 |
Why?
|
| Transplantation, Autologous | 36 | 2023 | 2124 | 1.400 |
Why?
|
| Immunotherapy, Adoptive | 13 | 2024 | 1270 | 1.400 |
Why?
|
| Animals | 216 | 2023 | 168757 | 1.390 |
Why?
|
| Myeloid Differentiation Factor 88 | 12 | 2023 | 571 | 1.390 |
Why?
|
| Hematologic Neoplasms | 16 | 2023 | 1832 | 1.380 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 13 | 3 | 2019 | 40 | 1.380 |
Why?
|
| Research Report | 5 | 2016 | 355 | 1.380 |
Why?
|
| Medical Oncology | 11 | 2017 | 2265 | 1.380 |
Why?
|
| Mice | 157 | 2023 | 81183 | 1.330 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 12 | 2023 | 452 | 1.310 |
Why?
|
| Vascular Endothelial Growth Factor A | 30 | 2011 | 3508 | 1.280 |
Why?
|
| Insulin-Like Growth Factor I | 26 | 2012 | 2015 | 1.280 |
Why?
|
| Cytokines | 31 | 2019 | 7322 | 1.270 |
Why?
|
| Phenylalanine | 4 | 2020 | 365 | 1.220 |
Why?
|
| Drug Evaluation, Preclinical | 18 | 2020 | 1375 | 1.220 |
Why?
|
| Cytotoxicity, Immunologic | 13 | 2020 | 1369 | 1.210 |
Why?
|
| Protein-Tyrosine Kinases | 12 | 2022 | 2455 | 1.200 |
Why?
|
| Maytansine | 7 | 2021 | 80 | 1.190 |
Why?
|
| Benzoquinones | 13 | 2013 | 201 | 1.180 |
Why?
|
| Coculture Techniques | 24 | 2021 | 1341 | 1.160 |
Why?
|
| DNA Damage | 13 | 2023 | 2432 | 1.160 |
Why?
|
| Platelet Transfusion | 3 | 2017 | 314 | 1.150 |
Why?
|
| Immunosuppressive Agents | 16 | 2018 | 4149 | 1.140 |
Why?
|
| Lactams, Macrocyclic | 14 | 2013 | 320 | 1.130 |
Why?
|
| Membrane Glycoproteins | 12 | 2021 | 3768 | 1.120 |
Why?
|
| Janus Kinases | 4 | 2020 | 244 | 1.100 |
Why?
|
| Histone Deacetylases | 8 | 2019 | 728 | 1.100 |
Why?
|
| Drug Delivery Systems | 17 | 2019 | 2219 | 1.090 |
Why?
|
| Maximum Tolerated Dose | 14 | 2021 | 892 | 1.090 |
Why?
|
| Phosphorylation | 39 | 2023 | 8436 | 1.090 |
Why?
|
| Paraproteinemias | 8 | 2019 | 246 | 1.080 |
Why?
|
| Adjuvants, Immunologic | 7 | 2006 | 1000 | 1.080 |
Why?
|
| DNA-Binding Proteins | 24 | 2020 | 9648 | 1.080 |
Why?
|
| Cysteine Proteinase Inhibitors | 7 | 2011 | 190 | 1.070 |
Why?
|
| Ubiquitin | 14 | 2023 | 852 | 1.070 |
Why?
|
| Prognosis | 69 | 2024 | 29063 | 1.060 |
Why?
|
| Dose-Response Relationship, Drug | 51 | 2019 | 10943 | 1.060 |
Why?
|
| Antigens, Neoplasm | 10 | 2019 | 1988 | 1.050 |
Why?
|
| Multienzyme Complexes | 12 | 2004 | 686 | 1.040 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 10 | 2023 | 307 | 1.040 |
Why?
|
| Doxorubicin | 20 | 2021 | 2234 | 1.020 |
Why?
|
| Telomerase | 11 | 2016 | 730 | 1.020 |
Why?
|
| Plasmacytoma | 10 | 2021 | 183 | 1.020 |
Why?
|
| Receptors, CXCR4 | 8 | 2021 | 726 | 1.010 |
Why?
|
| Protein Kinase Inhibitors | 19 | 2022 | 5535 | 1.010 |
Why?
|
| NAD | 3 | 2013 | 593 | 1.010 |
Why?
|
| Syndecan-1 | 11 | 2020 | 165 | 1.010 |
Why?
|
| Disease-Free Survival | 43 | 2022 | 6895 | 1.010 |
Why?
|
| Treatment Outcome | 106 | 2020 | 63114 | 1.010 |
Why?
|
| Pyrimidines | 12 | 2020 | 2942 | 1.000 |
Why?
|
| Cell Movement | 31 | 2020 | 5217 | 1.000 |
Why?
|
| Poly(ADP-ribose) Polymerases | 13 | 2016 | 440 | 0.980 |
Why?
|
| Gene Expression Profiling | 43 | 2023 | 9438 | 0.980 |
Why?
|
| Neovascularization, Pathologic | 22 | 2013 | 2635 | 0.980 |
Why?
|
| Leukocytes, Mononuclear | 12 | 2023 | 1836 | 0.960 |
Why?
|
| Cell Division | 34 | 2013 | 4568 | 0.950 |
Why?
|
| Down-Regulation | 23 | 2016 | 3002 | 0.930 |
Why?
|
| Receptors, Immunologic | 6 | 2021 | 1423 | 0.920 |
Why?
|
| MicroRNAs | 16 | 2023 | 3752 | 0.920 |
Why?
|
| Cancer Vaccines | 9 | 2019 | 1023 | 0.920 |
Why?
|
| Piperidines | 8 | 2021 | 1602 | 0.900 |
Why?
|
| Proto-Oncogene Proteins | 18 | 2020 | 4554 | 0.890 |
Why?
|
| Boron Compounds | 3 | 2015 | 178 | 0.870 |
Why?
|
| B-Lymphocytes | 16 | 2023 | 4665 | 0.860 |
Why?
|
| I-kappa B Kinase | 6 | 2014 | 252 | 0.860 |
Why?
|
| Etodolac | 3 | 2006 | 20 | 0.850 |
Why?
|
| RNA Splicing | 5 | 2023 | 907 | 0.850 |
Why?
|
| Ubiquitin Thiolesterase | 3 | 2017 | 449 | 0.850 |
Why?
|
| Arsenicals | 8 | 2017 | 124 | 0.840 |
Why?
|
| Acrylamides | 5 | 2018 | 255 | 0.840 |
Why?
|
| T-Lymphocytes | 19 | 2023 | 10180 | 0.840 |
Why?
|
| Peripheral Nervous System Diseases | 13 | 2014 | 685 | 0.820 |
Why?
|
| Blotting, Western | 24 | 2017 | 5179 | 0.820 |
Why?
|
| Immune Tolerance | 4 | 2018 | 2258 | 0.800 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 12 | 2016 | 1434 | 0.800 |
Why?
|
| Tumor Suppressor Proteins | 7 | 2020 | 2849 | 0.780 |
Why?
|
| Remission Induction | 17 | 2017 | 2386 | 0.780 |
Why?
|
| Pyrazoles | 6 | 2020 | 1972 | 0.770 |
Why?
|
| Osteolysis | 6 | 2015 | 270 | 0.770 |
Why?
|
| Oxides | 8 | 2017 | 405 | 0.760 |
Why?
|
| Indoles | 10 | 2022 | 1839 | 0.760 |
Why?
|
| Aged | 135 | 2022 | 163280 | 0.750 |
Why?
|
| Glycine | 3 | 2015 | 671 | 0.750 |
Why?
|
| MAP Kinase Signaling System | 7 | 2015 | 1526 | 0.740 |
Why?
|
| Osteonecrosis | 4 | 2014 | 227 | 0.740 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2020 | 67 | 0.730 |
Why?
|
| Histones | 9 | 2024 | 2599 | 0.730 |
Why?
|
| Immunization, Passive | 6 | 2005 | 623 | 0.730 |
Why?
|
| CD8-Positive T-Lymphocytes | 7 | 2020 | 4479 | 0.720 |
Why?
|
| Bone Resorption | 4 | 2018 | 723 | 0.720 |
Why?
|
| Aged, 80 and over | 71 | 2021 | 57776 | 0.720 |
Why?
|
| STAT Transcription Factors | 1 | 2020 | 182 | 0.720 |
Why?
|
| Receptors, CCR1 | 2 | 2011 | 33 | 0.710 |
Why?
|
| RNA, Small Interfering | 20 | 2018 | 3505 | 0.710 |
Why?
|
| Survival Rate | 34 | 2020 | 12788 | 0.710 |
Why?
|
| Cell Growth Processes | 12 | 2014 | 399 | 0.710 |
Why?
|
| Enzyme Activation | 21 | 2016 | 3701 | 0.710 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2020 | 135 | 0.700 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 7 | 2012 | 697 | 0.700 |
Why?
|
| Lymphocyte Activation | 19 | 2021 | 5524 | 0.700 |
Why?
|
| Benzylidene Compounds | 1 | 2019 | 27 | 0.700 |
Why?
|
| Mitogen-Activated Protein Kinases | 8 | 2023 | 1285 | 0.700 |
Why?
|
| Jaw Diseases | 3 | 2009 | 90 | 0.700 |
Why?
|
| Quinazolinones | 2 | 2012 | 221 | 0.690 |
Why?
|
| Phosphatidylinositol 3-Kinases | 11 | 2010 | 2938 | 0.690 |
Why?
|
| B-Cell Activating Factor | 3 | 2016 | 119 | 0.690 |
Why?
|
| Female | 185 | 2022 | 380194 | 0.690 |
Why?
|
| Cell Death | 12 | 2024 | 1706 | 0.690 |
Why?
|
| Male | 185 | 2021 | 350118 | 0.680 |
Why?
|
| Transmembrane Activator and CAML Interactor Protein | 2 | 2018 | 56 | 0.680 |
Why?
|
| Protein Kinase C | 5 | 2008 | 1227 | 0.670 |
Why?
|
| Thrombocytopenia | 8 | 2020 | 1179 | 0.670 |
Why?
|
| Kynurenine | 1 | 2019 | 139 | 0.670 |
Why?
|
| Middle Aged | 139 | 2021 | 213383 | 0.660 |
Why?
|
| Antineoplastic Agents, Alkylating | 4 | 2020 | 627 | 0.660 |
Why?
|
| Immunotoxins | 4 | 2015 | 179 | 0.650 |
Why?
|
| Galectins | 1 | 2021 | 268 | 0.650 |
Why?
|
| Neoplasm Transplantation | 20 | 2020 | 2085 | 0.650 |
Why?
|
| Flow Cytometry | 24 | 2017 | 5974 | 0.650 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 6 | 2012 | 480 | 0.650 |
Why?
|
| Epitopes, T-Lymphocyte | 4 | 2018 | 880 | 0.640 |
Why?
|
| Lymphocytes | 11 | 2013 | 2617 | 0.640 |
Why?
|
| Transplantation, Heterologous | 21 | 2015 | 2382 | 0.640 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 6 | 2012 | 489 | 0.640 |
Why?
|
| RNA Precursors | 1 | 2019 | 208 | 0.630 |
Why?
|
| Heat-Shock Proteins | 8 | 2008 | 822 | 0.620 |
Why?
|
| Growth Substances | 5 | 2006 | 784 | 0.620 |
Why?
|
| Cysteine Endopeptidases | 13 | 2012 | 563 | 0.610 |
Why?
|
| Combined Modality Therapy | 21 | 2020 | 8642 | 0.610 |
Why?
|
| Up-Regulation | 17 | 2020 | 4217 | 0.600 |
Why?
|
| Drug Design | 9 | 2017 | 1076 | 0.600 |
Why?
|
| Tryptophan | 1 | 2019 | 478 | 0.600 |
Why?
|
| Tumor Necrosis Factor-alpha | 13 | 2006 | 4420 | 0.600 |
Why?
|
| Chromosome Aberrations | 11 | 2022 | 1813 | 0.590 |
Why?
|
| Cell Cycle | 26 | 2017 | 2967 | 0.590 |
Why?
|
| Genomics | 14 | 2020 | 5720 | 0.590 |
Why?
|
| Reading | 1 | 2021 | 558 | 0.590 |
Why?
|
| Antigens, CD | 10 | 2021 | 4026 | 0.590 |
Why?
|
| Immunoblotting | 14 | 2014 | 1682 | 0.590 |
Why?
|
| Adaptor Proteins, Signal Transducing | 8 | 2023 | 2916 | 0.580 |
Why?
|
| Immunoglobulin M | 12 | 2023 | 1537 | 0.580 |
Why?
|
| Survival Analysis | 28 | 2020 | 10252 | 0.580 |
Why?
|
| Monocytes | 2 | 2016 | 2596 | 0.580 |
Why?
|
| Benzimidazoles | 4 | 2015 | 850 | 0.570 |
Why?
|
| Drug Screening Assays, Antitumor | 12 | 2017 | 730 | 0.570 |
Why?
|
| Drug Administration Schedule | 19 | 2020 | 4933 | 0.570 |
Why?
|
| Blood Proteins | 2 | 2021 | 1124 | 0.570 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 4 | 2014 | 215 | 0.570 |
Why?
|
| Proteomics | 7 | 2023 | 3638 | 0.570 |
Why?
|
| Proto-Oncogene Proteins c-myc | 7 | 2021 | 987 | 0.560 |
Why?
|
| Endothelial Growth Factors | 7 | 2003 | 694 | 0.560 |
Why?
|
| Antineoplastic Agents, Phytogenic | 5 | 2012 | 624 | 0.560 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 18 | 2016 | 3920 | 0.560 |
Why?
|
| Epigenesis, Genetic | 10 | 2024 | 3647 | 0.550 |
Why?
|
| Caspase 3 | 9 | 2016 | 758 | 0.540 |
Why?
|
| Lymphokines | 7 | 2003 | 949 | 0.540 |
Why?
|
| Transforming Growth Factor beta | 3 | 2017 | 2007 | 0.540 |
Why?
|
| Transcription Factors | 18 | 2023 | 12208 | 0.540 |
Why?
|
| Models, Biological | 16 | 2016 | 9583 | 0.540 |
Why?
|
| Estradiol | 7 | 2007 | 2020 | 0.530 |
Why?
|
| Thiophenes | 3 | 2017 | 588 | 0.530 |
Why?
|
| Disease Progression | 35 | 2022 | 13284 | 0.530 |
Why?
|
| Myeloid Cells | 2 | 2013 | 810 | 0.520 |
Why?
|
| Antibodies, Bispecific | 3 | 2023 | 164 | 0.520 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 2 | 2016 | 182 | 0.520 |
Why?
|
| Neoplasm Staging | 17 | 2024 | 11031 | 0.510 |
Why?
|
| Bone Marrow Neoplasms | 3 | 2017 | 104 | 0.510 |
Why?
|
| STAT3 Transcription Factor | 12 | 2017 | 873 | 0.510 |
Why?
|
| Purines | 3 | 2010 | 594 | 0.510 |
Why?
|
| Translocation, Genetic | 10 | 2021 | 1420 | 0.500 |
Why?
|
| Proteins | 8 | 2023 | 6103 | 0.490 |
Why?
|
| Cells, Cultured | 23 | 2020 | 19229 | 0.490 |
Why?
|
| Adult | 99 | 2022 | 214055 | 0.480 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2014 | 87 | 0.480 |
Why?
|
| Interferon Regulatory Factors | 1 | 2016 | 270 | 0.480 |
Why?
|
| Crk-Associated Substrate Protein | 2 | 2011 | 41 | 0.480 |
Why?
|
| Publications | 1 | 2016 | 195 | 0.470 |
Why?
|
| Clinical Trials, Phase III as Topic | 10 | 2020 | 841 | 0.470 |
Why?
|
| Proteoglycans | 4 | 2005 | 835 | 0.470 |
Why?
|
| Piperidones | 1 | 2013 | 28 | 0.470 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 4 | 2021 | 625 | 0.470 |
Why?
|
| Immunoglobulin D | 1 | 2013 | 56 | 0.470 |
Why?
|
| Caspase 9 | 8 | 2011 | 188 | 0.460 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2018 | 1990 | 0.460 |
Why?
|
| Endothelial Cells | 10 | 2021 | 3479 | 0.460 |
Why?
|
| Ubiquitin-Protein Ligases | 3 | 2020 | 1861 | 0.460 |
Why?
|
| Genes, Tumor Suppressor | 6 | 2023 | 1097 | 0.460 |
Why?
|
| Immunomodulation | 5 | 2020 | 541 | 0.460 |
Why?
|
| DNA, Neoplasm | 8 | 2020 | 1758 | 0.460 |
Why?
|
| Antibiotics, Antineoplastic | 5 | 2014 | 692 | 0.460 |
Why?
|
| Practice Guidelines as Topic | 13 | 2021 | 7279 | 0.450 |
Why?
|
| Piperazines | 6 | 2011 | 2488 | 0.450 |
Why?
|
| Lymphoma, B-Cell | 4 | 2022 | 931 | 0.450 |
Why?
|
| Lymphoma | 6 | 2022 | 1877 | 0.450 |
Why?
|
| Acetylation | 6 | 2018 | 1085 | 0.450 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 3 | 2006 | 664 | 0.450 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 2 | 2023 | 77 | 0.450 |
Why?
|
| Mesenchymal Stem Cells | 4 | 2019 | 1632 | 0.440 |
Why?
|
| Mutation | 30 | 2023 | 29786 | 0.440 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2016 | 504 | 0.440 |
Why?
|
| Sirtuins | 1 | 2015 | 323 | 0.440 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 12 | 2013 | 1676 | 0.440 |
Why?
|
| Genes, ras | 1 | 2015 | 690 | 0.440 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 4 | 2021 | 648 | 0.430 |
Why?
|
| Asthenia | 2 | 2010 | 16 | 0.430 |
Why?
|
| Cyclohexanones | 1 | 2012 | 30 | 0.430 |
Why?
|
| Acyltransferases | 2 | 2005 | 294 | 0.430 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2024 | 1736 | 0.430 |
Why?
|
| Neutropenia | 7 | 2023 | 895 | 0.430 |
Why?
|
| Proteome | 2 | 2020 | 1799 | 0.420 |
Why?
|
| Clodronic Acid | 2 | 2011 | 60 | 0.420 |
Why?
|
| Myeloma Proteins | 6 | 2017 | 72 | 0.420 |
Why?
|
| RNA, Messenger | 20 | 2020 | 13033 | 0.420 |
Why?
|
| Fibroma, Ossifying | 1 | 2012 | 19 | 0.420 |
Why?
|
| Gingival Neoplasms | 1 | 2012 | 22 | 0.420 |
Why?
|
| Depsipeptides | 3 | 2010 | 94 | 0.420 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 14 | 2014 | 4751 | 0.420 |
Why?
|
| Drug Therapy, Combination | 14 | 2017 | 6489 | 0.410 |
Why?
|
| Epoxy Compounds | 1 | 2012 | 136 | 0.410 |
Why?
|
| Receptors, Interleukin-6 | 5 | 2005 | 224 | 0.410 |
Why?
|
| Interleukin-10 | 2 | 2017 | 1200 | 0.410 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 13 | 2014 | 693 | 0.400 |
Why?
|
| Clinical Trials, Phase II as Topic | 10 | 2017 | 629 | 0.400 |
Why?
|
| Cell Adhesion Molecules | 4 | 2010 | 1602 | 0.390 |
Why?
|
| Metabolomics | 2 | 2017 | 1484 | 0.390 |
Why?
|
| Autophagy | 4 | 2013 | 1300 | 0.390 |
Why?
|
| Vascular Endothelial Growth Factors | 8 | 2006 | 772 | 0.390 |
Why?
|
| Sirolimus | 7 | 2014 | 1564 | 0.390 |
Why?
|
| Proto-Oncogene Proteins c-jun | 2 | 2013 | 286 | 0.380 |
Why?
|
| Pyridines | 7 | 2018 | 2825 | 0.380 |
Why?
|
| Adenine | 4 | 2021 | 936 | 0.380 |
Why?
|
| Endoribonucleases | 2 | 2012 | 229 | 0.380 |
Why?
|
| Azo Compounds | 2 | 2010 | 113 | 0.380 |
Why?
|
| G1 Phase | 1 | 2012 | 415 | 0.380 |
Why?
|
| High-Throughput Nucleotide Sequencing | 6 | 2021 | 3597 | 0.370 |
Why?
|
| Precancerous Conditions | 2 | 2011 | 975 | 0.370 |
Why?
|
| Mucin-1 | 4 | 2017 | 543 | 0.370 |
Why?
|
| Azepines | 3 | 2018 | 336 | 0.370 |
Why?
|
| Tumor Suppressor Protein p53 | 8 | 2020 | 2948 | 0.370 |
Why?
|
| Biological Products | 1 | 2019 | 860 | 0.370 |
Why?
|
| Caspase 8 | 7 | 2011 | 195 | 0.370 |
Why?
|
| Disease Models, Animal | 21 | 2019 | 18029 | 0.360 |
Why?
|
| Mitochondria | 10 | 2020 | 3520 | 0.360 |
Why?
|
| Cell Differentiation | 15 | 2016 | 11483 | 0.360 |
Why?
|
| Mitochondrial Proteins | 3 | 2006 | 996 | 0.360 |
Why?
|
| Drug Resistance, Multiple | 3 | 2005 | 252 | 0.360 |
Why?
|
| Transfection | 14 | 2013 | 5892 | 0.360 |
Why?
|
| I-kappa B Proteins | 6 | 2014 | 225 | 0.360 |
Why?
|
| Cyclin-Dependent Kinases | 4 | 2023 | 671 | 0.350 |
Why?
|
| Membrane Proteins | 10 | 2022 | 7880 | 0.350 |
Why?
|
| Nanoparticles | 4 | 2019 | 1905 | 0.350 |
Why?
|
| Cell Cycle Proteins | 8 | 2023 | 3462 | 0.350 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2023 | 1378 | 0.350 |
Why?
|
| Apoptosis Regulatory Proteins | 9 | 2015 | 1157 | 0.340 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2010 | 198 | 0.340 |
Why?
|
| Proto-Oncogene Proteins c-maf | 1 | 2009 | 71 | 0.340 |
Why?
|
| Follow-Up Studies | 29 | 2022 | 39050 | 0.340 |
Why?
|
| Fluorescent Antibody Technique | 8 | 2014 | 2505 | 0.340 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2018 | 2988 | 0.330 |
Why?
|
| Time Factors | 32 | 2020 | 40075 | 0.330 |
Why?
|
| Nerve Tissue Proteins | 2 | 2021 | 4462 | 0.330 |
Why?
|
| Cerulenin | 1 | 2008 | 7 | 0.330 |
Why?
|
| Tumor Burden | 10 | 2015 | 1915 | 0.320 |
Why?
|
| Data Interpretation, Statistical | 1 | 2018 | 2716 | 0.320 |
Why?
|
| Hydroquinones | 2 | 2009 | 36 | 0.320 |
Why?
|
| Proto-Oncogene Proteins c-hck | 3 | 2022 | 46 | 0.320 |
Why?
|
| MAP Kinase Kinase 2 | 2 | 2010 | 96 | 0.320 |
Why?
|
| Peer Review | 1 | 2010 | 209 | 0.320 |
Why?
|
| Research | 3 | 2016 | 1999 | 0.310 |
Why?
|
| Renal Insufficiency | 5 | 2014 | 804 | 0.310 |
Why?
|
| Randomized Controlled Trials as Topic | 15 | 2020 | 9959 | 0.310 |
Why?
|
| Administration, Oral | 10 | 2018 | 3913 | 0.310 |
Why?
|
| Isoenzymes | 5 | 2007 | 1726 | 0.310 |
Why?
|
| Receptors, Growth Factor | 2 | 2006 | 334 | 0.310 |
Why?
|
| Proto-Oncogene Proteins c-abl | 2 | 2014 | 146 | 0.310 |
Why?
|
| Mice, Inbred NOD | 13 | 2021 | 1878 | 0.310 |
Why?
|
| Cytotoxins | 2 | 2009 | 153 | 0.300 |
Why?
|
| Societies, Medical | 3 | 2020 | 3743 | 0.300 |
Why?
|
| Immunoglobulin E | 1 | 2013 | 1463 | 0.300 |
Why?
|
| Nuclear Proteins | 8 | 2023 | 5853 | 0.300 |
Why?
|
| Caveolin 1 | 2 | 2006 | 263 | 0.300 |
Why?
|
| Oleanolic Acid | 2 | 2004 | 43 | 0.300 |
Why?
|
| p21-Activated Kinases | 2 | 2018 | 128 | 0.290 |
Why?
|
| Cell Nucleus | 4 | 2004 | 2969 | 0.290 |
Why?
|
| Standard of Care | 1 | 2011 | 564 | 0.290 |
Why?
|
| Pharmacogenetics | 2 | 2008 | 675 | 0.290 |
Why?
|
| Fractures, Compression | 2 | 2018 | 133 | 0.290 |
Why?
|
| Tubulin | 3 | 2016 | 695 | 0.290 |
Why?
|
| Phorbol Esters | 1 | 2006 | 111 | 0.290 |
Why?
|
| Biomedical Research | 4 | 2017 | 3309 | 0.290 |
Why?
|
| Caveolae | 2 | 2006 | 57 | 0.290 |
Why?
|
| Leukemia, Plasma Cell | 2 | 2020 | 48 | 0.290 |
Why?
|
| Adamantane | 2 | 2009 | 173 | 0.290 |
Why?
|
| Peptides | 6 | 2018 | 4409 | 0.290 |
Why?
|
| Cell Line | 16 | 2013 | 15997 | 0.280 |
Why?
|
| DNA Repair | 7 | 2018 | 2046 | 0.280 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 5391 | 0.280 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2010 | 337 | 0.280 |
Why?
|
| Leukemia, B-Cell | 1 | 2006 | 86 | 0.280 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 2006 | 83 | 0.280 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2006 | 2282 | 0.280 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 10 | 2014 | 3870 | 0.280 |
Why?
|
| Transcription, Genetic | 11 | 2021 | 7722 | 0.280 |
Why?
|
| Transplantation Conditioning | 6 | 2020 | 1598 | 0.280 |
Why?
|
| beta Catenin | 9 | 2016 | 1059 | 0.280 |
Why?
|
| Peer Review, Research | 1 | 2009 | 329 | 0.270 |
Why?
|
| Prednisone | 10 | 2020 | 1574 | 0.270 |
Why?
|
| Naphthalenes | 1 | 2006 | 194 | 0.270 |
Why?
|
| Consensus | 9 | 2023 | 2959 | 0.270 |
Why?
|
| Kaplan-Meier Estimate | 14 | 2020 | 6538 | 0.270 |
Why?
|
| Anemia | 4 | 2011 | 1506 | 0.270 |
Why?
|
| Receptors, Transforming Growth Factor beta | 2 | 2004 | 314 | 0.270 |
Why?
|
| Oncogene Protein v-akt | 1 | 2006 | 135 | 0.270 |
Why?
|
| Glucocorticoids | 6 | 2009 | 2107 | 0.270 |
Why?
|
| Flavoproteins | 1 | 2005 | 43 | 0.270 |
Why?
|
| Recombinant Proteins | 12 | 2013 | 6622 | 0.270 |
Why?
|
| Rifabutin | 1 | 2005 | 52 | 0.270 |
Why?
|
| Superoxides | 2 | 2004 | 387 | 0.270 |
Why?
|
| IMP Dehydrogenase | 1 | 2005 | 34 | 0.270 |
Why?
|
| Spiro Compounds | 2 | 2005 | 76 | 0.260 |
Why?
|
| Hydrolases | 1 | 2006 | 139 | 0.260 |
Why?
|
| Azacitidine | 1 | 2007 | 347 | 0.260 |
Why?
|
| Hematology | 2 | 2021 | 221 | 0.260 |
Why?
|
| Propylene Glycols | 1 | 2005 | 92 | 0.260 |
Why?
|
| Quality of Life | 4 | 2022 | 12804 | 0.260 |
Why?
|
| Immunoglobulin G | 2 | 2014 | 4560 | 0.260 |
Why?
|
| Benzodiazepines | 4 | 2020 | 1101 | 0.260 |
Why?
|
| Antineoplastic Agents, Hormonal | 6 | 2020 | 1524 | 0.260 |
Why?
|
| Antigens, Surface | 2 | 2009 | 1663 | 0.260 |
Why?
|
| Chemokine CCL3 | 3 | 2011 | 83 | 0.250 |
Why?
|
| Drug Approval | 3 | 2014 | 742 | 0.250 |
Why?
|
| Chemokines, CXC | 2 | 2007 | 422 | 0.250 |
Why?
|
| Immunologic Memory | 3 | 2018 | 1348 | 0.250 |
Why?
|
| Epothilones | 1 | 2004 | 44 | 0.250 |
Why?
|
| Lignans | 1 | 2005 | 81 | 0.250 |
Why?
|
| Syndecans | 4 | 2005 | 79 | 0.250 |
Why?
|
| Endpoint Determination | 1 | 2007 | 601 | 0.250 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2004 | 102 | 0.250 |
Why?
|
| Gene Regulatory Networks | 2 | 2021 | 1708 | 0.250 |
Why?
|
| Organic Chemicals | 1 | 2005 | 211 | 0.250 |
Why?
|
| Membrane Potentials | 6 | 2005 | 1137 | 0.250 |
Why?
|
| Caveolins | 1 | 2004 | 104 | 0.240 |
Why?
|
| Antigens, CD20 | 2 | 2003 | 199 | 0.240 |
Why?
|
| Endodeoxyribonucleases | 1 | 2005 | 165 | 0.240 |
Why?
|
| MAP Kinase Kinase 4 | 4 | 2008 | 148 | 0.240 |
Why?
|
| Carrier Proteins | 7 | 2023 | 5021 | 0.240 |
Why?
|
| Neural Cell Adhesion Molecules | 2 | 2004 | 126 | 0.240 |
Why?
|
| Collagen Type I | 3 | 2016 | 592 | 0.240 |
Why?
|
| Bone Marrow Transplantation | 8 | 2015 | 2765 | 0.240 |
Why?
|
| Oncogenes | 5 | 2020 | 1265 | 0.240 |
Why?
|
| Genomic Instability | 4 | 2018 | 695 | 0.240 |
Why?
|
| Gene Knockdown Techniques | 4 | 2017 | 1655 | 0.240 |
Why?
|
| Lysine | 2 | 2021 | 1007 | 0.240 |
Why?
|
| Peptide Hydrolases | 2 | 2018 | 634 | 0.230 |
Why?
|
| Biological Therapy | 1 | 2005 | 138 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2023 | 33 | 0.230 |
Why?
|
| Kidney Diseases | 5 | 2018 | 2149 | 0.230 |
Why?
|
| RANK Ligand | 3 | 2012 | 326 | 0.230 |
Why?
|
| Antigens, Nuclear | 2 | 2014 | 192 | 0.230 |
Why?
|
| Phthalazines | 2 | 2003 | 363 | 0.220 |
Why?
|
| Ubiquitin-Protein Ligase Complexes | 1 | 2004 | 168 | 0.220 |
Why?
|
| Chemotaxis | 4 | 2009 | 607 | 0.220 |
Why?
|
| Chromosomes, Human, Pair 13 | 4 | 2021 | 197 | 0.220 |
Why?
|
| Drug Resistance | 4 | 2003 | 1609 | 0.220 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 3 | 2017 | 105 | 0.220 |
Why?
|
| Blood Component Transfusion | 1 | 2003 | 143 | 0.220 |
Why?
|
| Growth Inhibitors | 3 | 2005 | 385 | 0.220 |
Why?
|
| Lentivirus | 5 | 2013 | 501 | 0.220 |
Why?
|
| Bone Remodeling | 3 | 2014 | 575 | 0.220 |
Why?
|
| Aminopyridines | 2 | 2018 | 542 | 0.220 |
Why?
|
| Neoplasms, Second Primary | 4 | 2015 | 1061 | 0.220 |
Why?
|
| Benzamides | 3 | 2015 | 1379 | 0.220 |
Why?
|
| HCT116 Cells | 2 | 2021 | 408 | 0.220 |
Why?
|
| Fibronectins | 5 | 2011 | 726 | 0.220 |
Why?
|
| Anthracyclines | 1 | 2004 | 288 | 0.210 |
Why?
|
| Fatigue | 5 | 2022 | 1531 | 0.210 |
Why?
|
| CD40 Ligand | 4 | 2005 | 526 | 0.210 |
Why?
|
| Neoplasms, Experimental | 4 | 2017 | 1276 | 0.210 |
Why?
|
| Aspartic Acid Proteases | 1 | 2022 | 9 | 0.210 |
Why?
|
| NF-E2-Related Factor 1 | 1 | 2022 | 23 | 0.210 |
Why?
|
| Ascorbic Acid | 1 | 2006 | 651 | 0.210 |
Why?
|
| Structure-Activity Relationship | 4 | 2019 | 3129 | 0.210 |
Why?
|
| Sp1 Transcription Factor | 2 | 2014 | 144 | 0.210 |
Why?
|
| Endoplasmic Reticulum | 6 | 2009 | 1144 | 0.210 |
Why?
|
| Immunohistochemistry | 11 | 2015 | 11366 | 0.210 |
Why?
|
| Naphthoquinones | 1 | 2002 | 77 | 0.210 |
Why?
|
| Lymphopoiesis | 1 | 2023 | 135 | 0.210 |
Why?
|
| Transcriptional Activation | 4 | 2014 | 1783 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 3 | 2012 | 380 | 0.210 |
Why?
|
| Blood | 2 | 2004 | 598 | 0.210 |
Why?
|
| Biphenyl Compounds | 2 | 2012 | 913 | 0.210 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2007 | 1086 | 0.210 |
Why?
|
| Amino Acyl-tRNA Synthetases | 1 | 2023 | 93 | 0.210 |
Why?
|
| Spinal Fractures | 2 | 2018 | 696 | 0.210 |
Why?
|
| Cell Membrane | 5 | 2022 | 3748 | 0.210 |
Why?
|
| Agammaglobulinemia | 1 | 2023 | 167 | 0.210 |
Why?
|
| Genome, Human | 5 | 2019 | 4420 | 0.200 |
Why?
|
| Case-Control Studies | 13 | 2022 | 21746 | 0.200 |
Why?
|
| Protein Kinases | 3 | 2009 | 1640 | 0.200 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2020 | 1838 | 0.200 |
Why?
|
| Cytotoxicity Tests, Immunologic | 4 | 2006 | 329 | 0.200 |
Why?
|
| Semaphorins | 1 | 2022 | 101 | 0.200 |
Why?
|
| Interleukin-2 | 3 | 2007 | 1904 | 0.200 |
Why?
|
| Metformin | 2 | 2018 | 835 | 0.200 |
Why?
|
| Vincristine | 4 | 2009 | 1039 | 0.200 |
Why?
|
| DNA, Intergenic | 1 | 2022 | 107 | 0.200 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2021 | 59 | 0.200 |
Why?
|
| Organic Anion Transporters | 1 | 2022 | 100 | 0.200 |
Why?
|
| Camptothecin | 1 | 2004 | 576 | 0.200 |
Why?
|
| Alternative Splicing | 3 | 2023 | 1117 | 0.200 |
Why?
|
| Publishing | 1 | 2009 | 833 | 0.200 |
Why?
|
| Epigenomics | 2 | 2017 | 903 | 0.190 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2013 | 2942 | 0.190 |
Why?
|
| Neoplasms, Plasma Cell | 1 | 2021 | 36 | 0.190 |
Why?
|
| Fibroblasts | 1 | 2011 | 4161 | 0.190 |
Why?
|
| 5'-Nucleotidase | 1 | 2022 | 160 | 0.190 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2005 | 1660 | 0.190 |
Why?
|
| Luminescent Measurements | 3 | 2014 | 405 | 0.190 |
Why?
|
| Methylation | 3 | 2021 | 1106 | 0.190 |
Why?
|
| Phosphoproteins | 2 | 2014 | 2440 | 0.190 |
Why?
|
| Colony-Forming Units Assay | 4 | 2011 | 356 | 0.190 |
Why?
|
| Amyloidosis | 2 | 2007 | 795 | 0.190 |
Why?
|
| Disease Management | 5 | 2021 | 2459 | 0.190 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2020 | 71 | 0.190 |
Why?
|
| Lysosomes | 1 | 2005 | 893 | 0.190 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2022 | 17446 | 0.190 |
Why?
|
| HLA-A2 Antigen | 4 | 2013 | 213 | 0.190 |
Why?
|
| Herpesvirus 8, Human | 1 | 2002 | 258 | 0.180 |
Why?
|
| Oligonucleotides | 1 | 2003 | 572 | 0.180 |
Why?
|
| Graft vs Host Disease | 4 | 2020 | 2957 | 0.180 |
Why?
|
| TOR Serine-Threonine Kinases | 6 | 2014 | 2109 | 0.180 |
Why?
|
| Leukemia | 1 | 2008 | 1511 | 0.180 |
Why?
|
| Protein Folding | 3 | 2014 | 843 | 0.180 |
Why?
|
| Intercellular Adhesion Molecule-1 | 5 | 2009 | 1155 | 0.180 |
Why?
|
| Cell Fusion | 5 | 2010 | 297 | 0.180 |
Why?
|
| GTP Phosphohydrolases | 4 | 2020 | 509 | 0.180 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2015 | 295 | 0.180 |
Why?
|
| Gene Expression Regulation | 9 | 2013 | 12072 | 0.180 |
Why?
|
| Transplantation, Homologous | 8 | 2020 | 4776 | 0.180 |
Why?
|
| Telomere | 6 | 2008 | 910 | 0.180 |
Why?
|
| Ribosomes | 1 | 2023 | 500 | 0.180 |
Why?
|
| Histone Demethylases | 2 | 2023 | 321 | 0.180 |
Why?
|
| Immunophenotyping | 5 | 2014 | 1880 | 0.170 |
Why?
|
| 14-3-3 Proteins | 1 | 2020 | 214 | 0.170 |
Why?
|
| Interferon-gamma | 7 | 2015 | 3206 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2022 | 322 | 0.170 |
Why?
|
| Receptors, IgG | 3 | 2008 | 582 | 0.170 |
Why?
|
| Nucleotidyltransferases | 1 | 2021 | 220 | 0.170 |
Why?
|
| Immunity, Cellular | 5 | 2013 | 1607 | 0.170 |
Why?
|
| DNA Mutational Analysis | 8 | 2020 | 4186 | 0.170 |
Why?
|
| Antibodies | 3 | 2018 | 2460 | 0.170 |
Why?
|
| Indazoles | 2 | 2013 | 289 | 0.170 |
Why?
|
| Cytochrome c Group | 3 | 2003 | 128 | 0.170 |
Why?
|
| Phosphoramide Mustards | 1 | 2018 | 16 | 0.170 |
Why?
|
| Myosin Heavy Chains | 1 | 2020 | 414 | 0.170 |
Why?
|
| Bone and Bones | 5 | 2015 | 2575 | 0.170 |
Why?
|
| Hematopoiesis | 4 | 2020 | 2072 | 0.170 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2017 | 288 | 0.170 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2018 | 2540 | 0.170 |
Why?
|
| Oximes | 2 | 2022 | 311 | 0.170 |
Why?
|
| Single-Chain Antibodies | 1 | 2019 | 108 | 0.170 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2010 | 323 | 0.160 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2022 | 1381 | 0.160 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2022 | 2649 | 0.160 |
Why?
|
| Polysaccharides | 1 | 2005 | 1053 | 0.160 |
Why?
|
| Proto-Oncogene Proteins B-raf | 6 | 2023 | 2043 | 0.160 |
Why?
|
| Mutagenesis | 2 | 2018 | 1266 | 0.160 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2009 | 627 | 0.160 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2020 | 416 | 0.160 |
Why?
|
| Protein Binding | 7 | 2019 | 9386 | 0.160 |
Why?
|
| History, 21st Century | 2 | 2015 | 1534 | 0.160 |
Why?
|
| RNA Interference | 8 | 2019 | 2889 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2022 | 538 | 0.160 |
Why?
|
| Receptors, Glucocorticoid | 3 | 2013 | 302 | 0.160 |
Why?
|
| TCF Transcription Factors | 3 | 2008 | 140 | 0.160 |
Why?
|
| Risk Factors | 20 | 2022 | 72290 | 0.160 |
Why?
|
| Paracrine Communication | 3 | 2006 | 277 | 0.160 |
Why?
|
| Culture Media, Serum-Free | 3 | 2009 | 158 | 0.160 |
Why?
|
| Immunity | 2 | 2021 | 1012 | 0.160 |
Why?
|
| DNA Copy Number Variations | 4 | 2021 | 1941 | 0.160 |
Why?
|
| Osteoblasts | 5 | 2013 | 1166 | 0.160 |
Why?
|
| Transcription Factor RelA | 2 | 2014 | 275 | 0.160 |
Why?
|
| Retreatment | 2 | 2018 | 610 | 0.160 |
Why?
|
| Cluster Analysis | 5 | 2015 | 2715 | 0.160 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 2010 | 404 | 0.160 |
Why?
|
| Immunologic Surveillance | 1 | 2018 | 93 | 0.160 |
Why?
|
| Injections, Subcutaneous | 1 | 2019 | 666 | 0.160 |
Why?
|
| RNA | 3 | 2023 | 2749 | 0.150 |
Why?
|
| Lymphocyte Transfusion | 3 | 2003 | 236 | 0.150 |
Why?
|
| Receptor, IGF Type 1 | 3 | 2005 | 390 | 0.150 |
Why?
|
| Endonucleases | 1 | 2020 | 380 | 0.150 |
Why?
|
| Nitroimidazoles | 1 | 2018 | 106 | 0.150 |
Why?
|
| Cisplatin | 2 | 2021 | 1662 | 0.150 |
Why?
|
| Chemokine CXCL12 | 4 | 2009 | 464 | 0.150 |
Why?
|
| Neoplastic Stem Cells | 6 | 2019 | 1376 | 0.150 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2017 | 33 | 0.150 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2020 | 659 | 0.150 |
Why?
|
| Breast Neoplasms | 4 | 2022 | 20822 | 0.150 |
Why?
|
| Random Allocation | 2 | 2012 | 2429 | 0.150 |
Why?
|
| Protein Subunits | 2 | 2012 | 959 | 0.150 |
Why?
|
| Terphenyl Compounds | 1 | 2016 | 7 | 0.150 |
Why?
|
| Vitamins | 1 | 2006 | 1622 | 0.150 |
Why?
|
| Ikaros Transcription Factor | 1 | 2018 | 217 | 0.150 |
Why?
|
| Peptide Fragments | 6 | 2016 | 5097 | 0.150 |
Why?
|
| Sulfonamides | 1 | 2006 | 1938 | 0.150 |
Why?
|
| Cyclopentanes | 2 | 2018 | 91 | 0.150 |
Why?
|
| Anticarcinogenic Agents | 2 | 2010 | 253 | 0.150 |
Why?
|
| Electrophoretic Mobility Shift Assay | 3 | 2007 | 300 | 0.150 |
Why?
|
| Nitriles | 2 | 2020 | 956 | 0.150 |
Why?
|
| Mice, Nude | 6 | 2018 | 3689 | 0.150 |
Why?
|
| Hematinics | 2 | 2011 | 281 | 0.140 |
Why?
|
| Sulfides | 1 | 2017 | 165 | 0.140 |
Why?
|
| Macrophage Colony-Stimulating Factor | 2 | 2007 | 193 | 0.140 |
Why?
|
| Nitrogen Mustard Compounds | 2 | 2014 | 45 | 0.140 |
Why?
|
| Stem Cell Niche | 2 | 2018 | 346 | 0.140 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2017 | 2016 | 0.140 |
Why?
|
| Immunoglobulins | 3 | 2017 | 881 | 0.140 |
Why?
|
| Pyridazines | 2 | 2012 | 202 | 0.140 |
Why?
|
| Tubulin Modulators | 2 | 2007 | 110 | 0.140 |
Why?
|
| DNA Helicases | 1 | 2002 | 859 | 0.140 |
Why?
|
| Cell Lineage | 3 | 2021 | 2504 | 0.140 |
Why?
|
| K562 Cells | 5 | 2013 | 634 | 0.140 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2015 | 43 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 14 | 3 | 2020 | 299 | 0.140 |
Why?
|
| Health Services for the Aged | 1 | 2018 | 269 | 0.140 |
Why?
|
| Cell Count | 2 | 2017 | 1856 | 0.140 |
Why?
|
| Health Planning | 1 | 2017 | 238 | 0.140 |
Why?
|
| Models, Animal | 3 | 2007 | 2171 | 0.130 |
Why?
|
| Molecular Chaperones | 3 | 2007 | 742 | 0.130 |
Why?
|
| Glycolysis | 1 | 2020 | 827 | 0.130 |
Why?
|
| Heterocyclic Compounds | 3 | 2019 | 249 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 4 | 3 | 2020 | 374 | 0.130 |
Why?
|
| Health Facilities | 1 | 2021 | 573 | 0.130 |
Why?
|
| Treatment Failure | 4 | 2022 | 2618 | 0.130 |
Why?
|
| Platelet Count | 3 | 2010 | 781 | 0.130 |
Why?
|
| Procollagen | 1 | 2016 | 185 | 0.130 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2006 | 1596 | 0.130 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2015 | 75 | 0.130 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2017 | 3479 | 0.130 |
Why?
|
| Alleles | 4 | 2021 | 6933 | 0.130 |
Why?
|
| RNA-Binding Proteins | 2 | 2023 | 1903 | 0.130 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 3 | 2003 | 552 | 0.130 |
Why?
|
| Stem Cells | 3 | 2018 | 3567 | 0.130 |
Why?
|
| Cyclophilin A | 1 | 2015 | 57 | 0.130 |
Why?
|
| Patient Selection | 3 | 2017 | 4215 | 0.130 |
Why?
|
| Microscopy, Fluorescence | 3 | 2011 | 2699 | 0.130 |
Why?
|
| Mutagens | 1 | 2015 | 168 | 0.130 |
Why?
|
| Nausea | 3 | 2012 | 673 | 0.130 |
Why?
|
| Promoter Regions, Genetic | 4 | 2018 | 5867 | 0.130 |
Why?
|
| Leupeptins | 5 | 2009 | 122 | 0.130 |
Why?
|
| Internationality | 1 | 2020 | 1003 | 0.130 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2013 | 1790 | 0.130 |
Why?
|
| RNA, Neoplasm | 3 | 2009 | 769 | 0.130 |
Why?
|
| Chymotrypsin | 2 | 2016 | 149 | 0.130 |
Why?
|
| Kinetics | 2 | 2016 | 6473 | 0.130 |
Why?
|
| Germinal Center | 3 | 2023 | 377 | 0.120 |
Why?
|
| Gene Expression | 5 | 2018 | 7799 | 0.120 |
Why?
|
| Focal Adhesion Kinase 2 | 1 | 2014 | 86 | 0.120 |
Why?
|
| Genes, bcl-2 | 2 | 2005 | 122 | 0.120 |
Why?
|
| Phenylurea Compounds | 1 | 2018 | 528 | 0.120 |
Why?
|
| Substrate Specificity | 4 | 2017 | 1801 | 0.120 |
Why?
|
| Response Elements | 1 | 2016 | 312 | 0.120 |
Why?
|
| Health Priorities | 1 | 2017 | 380 | 0.120 |
Why?
|
| Inhibitory Concentration 50 | 4 | 2011 | 459 | 0.120 |
Why?
|
| Green Fluorescent Proteins | 5 | 2014 | 2088 | 0.120 |
Why?
|
| Ligands | 4 | 2008 | 3282 | 0.120 |
Why?
|
| Anniversaries and Special Events | 1 | 2015 | 89 | 0.120 |
Why?
|
| Thiazoles | 3 | 2010 | 1483 | 0.120 |
Why?
|
| Heavy Chain Disease | 1 | 2014 | 19 | 0.120 |
Why?
|
| Geriatric Assessment | 2 | 2015 | 1372 | 0.120 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 3 | 2005 | 197 | 0.120 |
Why?
|
| Antigens, CD34 | 3 | 2005 | 657 | 0.120 |
Why?
|
| Membrane Potential, Mitochondrial | 2 | 2012 | 297 | 0.120 |
Why?
|
| Mass Spectrometry | 3 | 2014 | 2203 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2022 | 15519 | 0.120 |
Why?
|
| Chromatin | 3 | 2023 | 2934 | 0.120 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2017 | 491 | 0.120 |
Why?
|
| Cryoglobulinemia | 2 | 2012 | 87 | 0.120 |
Why?
|
| Trans-Activators | 4 | 2005 | 2924 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 4 | 2015 | 6171 | 0.120 |
Why?
|
| Anthracenes | 2 | 2003 | 84 | 0.120 |
Why?
|
| United States | 16 | 2020 | 69872 | 0.120 |
Why?
|
| Morpholines | 2 | 2014 | 571 | 0.110 |
Why?
|
| Molecular Structure | 3 | 2017 | 1899 | 0.110 |
Why?
|
| HSP27 Heat-Shock Proteins | 2 | 2003 | 70 | 0.110 |
Why?
|
| Dermatitis, Contact | 1 | 2013 | 129 | 0.110 |
Why?
|
| HLA-D Antigens | 1 | 2013 | 134 | 0.110 |
Why?
|
| Biological Availability | 2 | 2011 | 397 | 0.110 |
Why?
|
| Protein Conformation | 2 | 2019 | 4011 | 0.110 |
Why?
|
| Hematologic Diseases | 3 | 2019 | 498 | 0.110 |
Why?
|
| Epidemiologic Methods | 2 | 2008 | 1364 | 0.110 |
Why?
|
| Reactive Oxygen Species | 4 | 2017 | 2077 | 0.110 |
Why?
|
| Drug Discovery | 2 | 2011 | 1058 | 0.110 |
Why?
|
| Griseofulvin | 1 | 2012 | 7 | 0.110 |
Why?
|
| Drug Interactions | 3 | 2022 | 1460 | 0.110 |
Why?
|
| Exosomes | 2 | 2019 | 417 | 0.110 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2018 | 3523 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 2012 | 34 | 0.110 |
Why?
|
| Neoadjuvant Therapy | 3 | 2020 | 2728 | 0.110 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2012 | 68 | 0.110 |
Why?
|
| United States Food and Drug Administration | 4 | 2014 | 1584 | 0.110 |
Why?
|
| Cryoglobulins | 1 | 2012 | 59 | 0.110 |
Why?
|
| Immunoprecipitation | 3 | 2014 | 905 | 0.110 |
Why?
|
| Umbilical Veins | 2 | 2010 | 433 | 0.110 |
Why?
|
| Adrenergic beta-2 Receptor Antagonists | 1 | 2012 | 9 | 0.110 |
Why?
|
| Drugs, Investigational | 1 | 2015 | 214 | 0.110 |
Why?
|
| Oxazines | 1 | 2014 | 298 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 5 | 2018 | 4803 | 0.110 |
Why?
|
| RNA, Antisense | 1 | 2013 | 138 | 0.110 |
Why?
|
| Plant Growth Regulators | 1 | 2012 | 50 | 0.110 |
Why?
|
| Oxylipins | 1 | 2012 | 49 | 0.110 |
Why?
|
| Galectin 3 | 2 | 2023 | 227 | 0.110 |
Why?
|
| Active Transport, Cell Nucleus | 3 | 2014 | 443 | 0.110 |
Why?
|
| Asymptomatic Diseases | 2 | 2014 | 551 | 0.110 |
Why?
|
| Adenosine A2 Receptor Antagonists | 1 | 2012 | 48 | 0.100 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 6773 | 0.100 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2012 | 63 | 0.100 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 1678 | 0.100 |
Why?
|
| Cyclins | 2 | 2005 | 603 | 0.100 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2018 | 1341 | 0.100 |
Why?
|
| Biopsy | 5 | 2019 | 6756 | 0.100 |
Why?
|
| Influenza, Human | 1 | 2023 | 1479 | 0.100 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2012 | 80 | 0.100 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 1071 | 0.100 |
Why?
|
| Gene Dosage | 3 | 2018 | 1252 | 0.100 |
Why?
|
| Glycoproteins | 3 | 2006 | 2263 | 0.100 |
Why?
|
| Prospective Studies | 13 | 2023 | 53288 | 0.100 |
Why?
|
| Repressor Proteins | 3 | 2022 | 3023 | 0.100 |
Why?
|
| Small Molecule Libraries | 1 | 2017 | 720 | 0.100 |
Why?
|
| Chromosome Deletion | 3 | 2021 | 1401 | 0.100 |
Why?
|
| Pandemics | 2 | 2023 | 8388 | 0.100 |
Why?
|
| Protein Engineering | 1 | 2015 | 540 | 0.100 |
Why?
|
| High-Throughput Screening Assays | 3 | 2012 | 944 | 0.100 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2014 | 1213 | 0.100 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2012 | 83 | 0.100 |
Why?
|
| Antibodies, Neutralizing | 2 | 2013 | 1978 | 0.100 |
Why?
|
| Receptors, Cell Surface | 5 | 2012 | 2866 | 0.100 |
Why?
|
| Thiocyanates | 1 | 2011 | 70 | 0.100 |
Why?
|
| Diketopiperazines | 1 | 2011 | 20 | 0.100 |
Why?
|
| Isothiocyanates | 1 | 2011 | 51 | 0.100 |
Why?
|
| ras Proteins | 2 | 2014 | 1060 | 0.100 |
Why?
|
| Integrin alpha4 | 1 | 2011 | 92 | 0.100 |
Why?
|
| eIF-2 Kinase | 1 | 2012 | 149 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2012 | 365 | 0.100 |
Why?
|
| Polydeoxyribonucleotides | 2 | 2010 | 127 | 0.100 |
Why?
|
| Antigen-Presenting Cells | 1 | 2015 | 973 | 0.100 |
Why?
|
| Pteridines | 1 | 2011 | 45 | 0.100 |
Why?
|
| Arthritis, Experimental | 1 | 2013 | 291 | 0.100 |
Why?
|
| Proportional Hazards Models | 6 | 2024 | 12354 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2012 | 130 | 0.100 |
Why?
|
| Centrosome | 1 | 2012 | 201 | 0.100 |
Why?
|
| Acetates | 1 | 2012 | 311 | 0.100 |
Why?
|
| Education, Medical, Continuing | 2 | 2014 | 840 | 0.100 |
Why?
|
| Neovascularization, Physiologic | 4 | 2006 | 1351 | 0.100 |
Why?
|
| HLA-DR Antigens | 1 | 2013 | 645 | 0.100 |
Why?
|
| Hospice Care | 1 | 2018 | 672 | 0.100 |
Why?
|
| Diagnosis, Differential | 3 | 2014 | 12959 | 0.100 |
Why?
|
| Acid Phosphatase | 2 | 2007 | 143 | 0.100 |
Why?
|
| Antigen Presentation | 3 | 2007 | 1284 | 0.100 |
Why?
|
| Wnt Proteins | 3 | 2009 | 721 | 0.090 |
Why?
|
| Genetic Testing | 2 | 2017 | 3444 | 0.090 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2009 | 3386 | 0.090 |
Why?
|
| src-Family Kinases | 2 | 2022 | 551 | 0.090 |
Why?
|
| Incidence | 8 | 2017 | 20947 | 0.090 |
Why?
|
| Gene Frequency | 2 | 2020 | 3588 | 0.090 |
Why?
|
| 3' Untranslated Regions | 3 | 2020 | 513 | 0.090 |
Why?
|
| Blood Coagulation Factors | 1 | 2012 | 355 | 0.090 |
Why?
|
| Exons | 3 | 2022 | 2437 | 0.090 |
Why?
|
| Luminescent Proteins | 2 | 2003 | 853 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2013 | 8301 | 0.090 |
Why?
|
| Endothelium, Vascular | 3 | 2010 | 4456 | 0.090 |
Why?
|
| Chromatography, Liquid | 1 | 2014 | 976 | 0.090 |
Why?
|
| Clone Cells | 2 | 2018 | 1692 | 0.090 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 934 | 0.090 |
Why?
|
| Unfolded Protein Response | 1 | 2012 | 233 | 0.090 |
Why?
|
| Back Pain | 1 | 2014 | 545 | 0.090 |
Why?
|
| Diabetes Mellitus | 2 | 2018 | 5751 | 0.090 |
Why?
|
| DNA | 5 | 2017 | 7301 | 0.090 |
Why?
|
| Ubiquitins | 1 | 2012 | 384 | 0.090 |
Why?
|
| SUMO-1 Protein | 1 | 2009 | 35 | 0.090 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2017 | 1692 | 0.090 |
Why?
|
| Subtraction Technique | 2 | 2003 | 525 | 0.090 |
Why?
|
| Oncogene Protein pp60(v-src) | 1 | 2009 | 77 | 0.090 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2023 | 903 | 0.090 |
Why?
|
| Frail Elderly | 1 | 2015 | 693 | 0.090 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2012 | 279 | 0.090 |
Why?
|
| Polymorphism, Genetic | 3 | 2022 | 4328 | 0.090 |
Why?
|
| Multiprotein Complexes | 2 | 2015 | 1119 | 0.090 |
Why?
|
| Hexokinase | 1 | 2010 | 125 | 0.090 |
Why?
|
| Organizational Objectives | 1 | 2012 | 438 | 0.090 |
Why?
|
| Mice, Transgenic | 8 | 2020 | 9734 | 0.090 |
Why?
|
| beta 2-Microglobulin | 2 | 2012 | 315 | 0.090 |
Why?
|
| Stress, Physiological | 3 | 2012 | 1403 | 0.090 |
Why?
|
| Transcriptional Elongation Factors | 2 | 2022 | 166 | 0.090 |
Why?
|
| Safety | 2 | 2006 | 1186 | 0.090 |
Why?
|
| Genotype | 5 | 2018 | 12951 | 0.090 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinase 2 | 1 | 2009 | 33 | 0.090 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2010 | 175 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2005 | 1677 | 0.090 |
Why?
|
| Dental Fistula | 1 | 2009 | 13 | 0.090 |
Why?
|
| Edema | 1 | 2013 | 789 | 0.090 |
Why?
|
| Peptides, Cyclic | 2 | 2010 | 400 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2010 | 193 | 0.090 |
Why?
|
| Lymphocyte Culture Test, Mixed | 3 | 2005 | 517 | 0.090 |
Why?
|
| Editorial Policies | 1 | 2014 | 451 | 0.090 |
Why?
|
| Cell Tracking | 1 | 2011 | 145 | 0.090 |
Why?
|
| Age Factors | 4 | 2019 | 18370 | 0.090 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2013 | 523 | 0.080 |
Why?
|
| Nitrofurans | 1 | 2008 | 6 | 0.080 |
Why?
|
| Sensation Disorders | 1 | 2010 | 155 | 0.080 |
Why?
|
| T-Cell Antigen Receptor Specificity | 2 | 2019 | 87 | 0.080 |
Why?
|
| Molecular Sequence Data | 5 | 2013 | 18111 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 10 | 2021 | 21827 | 0.080 |
Why?
|
| Models, Genetic | 1 | 2019 | 3494 | 0.080 |
Why?
|
| Receptors, Cytokine | 1 | 2009 | 261 | 0.080 |
Why?
|
| Vaccination | 2 | 2019 | 3278 | 0.080 |
Why?
|
| Urochordata | 1 | 2008 | 21 | 0.080 |
Why?
|
| Drug Dosage Calculations | 1 | 2009 | 114 | 0.080 |
Why?
|
| Forecasting | 4 | 2017 | 2951 | 0.080 |
Why?
|
| CpG Islands | 2 | 2011 | 1172 | 0.080 |
Why?
|
| Infusions, Intravenous | 2 | 2011 | 2274 | 0.080 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2007 | 215 | 0.080 |
Why?
|
| Maxillary Diseases | 1 | 2008 | 51 | 0.080 |
Why?
|
| Urea | 1 | 2011 | 450 | 0.080 |
Why?
|
| DNA, Complementary | 3 | 2013 | 2050 | 0.080 |
Why?
|
| Research Design | 2 | 2018 | 5987 | 0.080 |
Why?
|
| Activins | 1 | 2010 | 208 | 0.080 |
Why?
|
| Product Labeling | 1 | 2009 | 79 | 0.080 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2009 | 115 | 0.080 |
Why?
|
| Cyclophosphamide | 4 | 2021 | 2242 | 0.080 |
Why?
|
| Lipopolysaccharides | 2 | 2013 | 2216 | 0.080 |
Why?
|
| Genome-Wide Association Study | 4 | 2022 | 12261 | 0.080 |
Why?
|
| Anilides | 2 | 2016 | 408 | 0.080 |
Why?
|
| Hypertension | 2 | 2018 | 8480 | 0.080 |
Why?
|
| Antigens, Viral | 2 | 2003 | 1035 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2015 | 3772 | 0.080 |
Why?
|
| Ubiquitination | 3 | 2020 | 1012 | 0.080 |
Why?
|
| Cytogenetics | 2 | 2020 | 203 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2009 | 227 | 0.080 |
Why?
|
| Cytoprotection | 1 | 2009 | 210 | 0.080 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2009 | 708 | 0.080 |
Why?
|
| Hypercalcemia | 1 | 2011 | 409 | 0.080 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2009 | 237 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 1972 | 0.080 |
Why?
|
| Depression, Chemical | 1 | 2007 | 191 | 0.080 |
Why?
|
| Bone Diseases, Metabolic | 2 | 2010 | 417 | 0.080 |
Why?
|
| Genetic Heterogeneity | 2 | 2014 | 733 | 0.080 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2009 | 222 | 0.080 |
Why?
|
| Chick Embryo | 2 | 2010 | 982 | 0.080 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2009 | 241 | 0.080 |
Why?
|
| Seawater | 1 | 2008 | 121 | 0.080 |
Why?
|
| Deoxycytidine | 1 | 2012 | 826 | 0.080 |
Why?
|
| Benzylamines | 3 | 2019 | 223 | 0.080 |
Why?
|
| Graft vs Tumor Effect | 2 | 2005 | 72 | 0.080 |
Why?
|
| Chemokine CCL4 | 1 | 2007 | 128 | 0.080 |
Why?
|
| Chemokines | 1 | 2012 | 970 | 0.080 |
Why?
|
| Niacinamide | 1 | 2010 | 417 | 0.080 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 2 | 2009 | 195 | 0.080 |
Why?
|
| Mandibular Diseases | 1 | 2008 | 119 | 0.080 |
Why?
|
| Oral Ulcer | 1 | 2008 | 96 | 0.080 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2007 | 122 | 0.080 |
Why?
|
| Dipeptides | 1 | 2010 | 409 | 0.080 |
Why?
|
| Prevalence | 2 | 2017 | 15226 | 0.080 |
Why?
|
| Gene Transfer Techniques | 1 | 2013 | 1224 | 0.080 |
Why?
|
| Guidelines as Topic | 1 | 2014 | 1405 | 0.080 |
Why?
|
| Organ Specificity | 1 | 2012 | 2008 | 0.080 |
Why?
|
| Hedgehog Proteins | 1 | 2012 | 783 | 0.070 |
Why?
|
| Genes, fos | 1 | 2007 | 183 | 0.070 |
Why?
|
| Fluorouracil | 1 | 2012 | 1619 | 0.070 |
Why?
|
| Cytogenetic Analysis | 2 | 2020 | 295 | 0.070 |
Why?
|
| Bone Neoplasms | 2 | 2017 | 2529 | 0.070 |
Why?
|
| Thrombocytosis | 1 | 2007 | 81 | 0.070 |
Why?
|
| Stilbenes | 1 | 2008 | 156 | 0.070 |
Why?
|
| Protein Transport | 2 | 2004 | 1988 | 0.070 |
Why?
|
| Cell Fractionation | 2 | 2011 | 252 | 0.070 |
Why?
|
| Cyclin D2 | 2 | 2018 | 101 | 0.070 |
Why?
|
| Mandible | 1 | 2012 | 740 | 0.070 |
Why?
|
| Risk | 5 | 2015 | 9687 | 0.070 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2007 | 111 | 0.070 |
Why?
|
| Liposomes | 2 | 2014 | 759 | 0.070 |
Why?
|
| History, 20th Century | 1 | 2015 | 2740 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2016 | 4386 | 0.070 |
Why?
|
| Authorship | 1 | 2010 | 271 | 0.070 |
Why?
|
| Diagnostic Imaging | 2 | 2019 | 3507 | 0.070 |
Why?
|
| Drug Evaluation | 1 | 2008 | 647 | 0.070 |
Why?
|
| Protein Array Analysis | 2 | 2012 | 411 | 0.070 |
Why?
|
| Watchful Waiting | 1 | 2011 | 492 | 0.070 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2007 | 189 | 0.070 |
Why?
|
| Foundations | 1 | 2006 | 94 | 0.070 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2006 | 65 | 0.070 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 2007 | 131 | 0.070 |
Why?
|
| Germ Cells | 2 | 2022 | 631 | 0.070 |
Why?
|
| Rats | 4 | 2013 | 24260 | 0.070 |
Why?
|
| Leukocyte Count | 1 | 2010 | 1588 | 0.070 |
Why?
|
| Catechin | 1 | 2006 | 66 | 0.070 |
Why?
|
| Transplantation Immunology | 1 | 2008 | 546 | 0.070 |
Why?
|
| Oxidation-Reduction | 3 | 2017 | 2187 | 0.070 |
Why?
|
| Chimera | 1 | 2007 | 485 | 0.070 |
Why?
|
| Sequence Analysis, RNA | 3 | 2022 | 2012 | 0.070 |
Why?
|
| Wiskott-Aldrich Syndrome Protein | 1 | 2007 | 160 | 0.070 |
Why?
|
| Twins, Monozygotic | 2 | 2008 | 458 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 3 | 2014 | 3616 | 0.070 |
Why?
|
| Terminal Care | 1 | 2018 | 1694 | 0.070 |
Why?
|
| Risk Management | 1 | 2010 | 571 | 0.070 |
Why?
|
| Delivery of Health Care | 2 | 2021 | 5319 | 0.070 |
Why?
|
| Erythrocyte Transfusion | 1 | 2011 | 565 | 0.070 |
Why?
|
| Leukocytosis | 1 | 2007 | 247 | 0.070 |
Why?
|
| Toll-Like Receptors | 1 | 2009 | 592 | 0.070 |
Why?
|
| Injections, Intravenous | 1 | 2008 | 1420 | 0.070 |
Why?
|
| Chorioallantoic Membrane | 1 | 2006 | 47 | 0.070 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2010 | 890 | 0.070 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2006 | 154 | 0.070 |
Why?
|
| Herpes Zoster | 1 | 2008 | 264 | 0.070 |
Why?
|
| Valproic Acid | 1 | 2008 | 445 | 0.070 |
Why?
|
| Double-Blind Method | 3 | 2017 | 12026 | 0.070 |
Why?
|
| DNA Replication | 4 | 2019 | 1399 | 0.070 |
Why?
|
| Molecular Mimicry | 1 | 2006 | 201 | 0.070 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 1504 | 0.070 |
Why?
|
| Apoptosis Inducing Factor | 1 | 2005 | 55 | 0.070 |
Why?
|
| Vidarabine | 3 | 2014 | 345 | 0.070 |
Why?
|
| Holography | 1 | 2006 | 84 | 0.070 |
Why?
|
| Angiopoietin-1 | 1 | 2006 | 114 | 0.070 |
Why?
|
| Somatomedins | 1 | 2006 | 192 | 0.070 |
Why?
|
| Biometry | 1 | 2009 | 558 | 0.070 |
Why?
|
| raf Kinases | 1 | 2005 | 122 | 0.070 |
Why?
|
| Enzyme Precursors | 2 | 2002 | 176 | 0.070 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2009 | 484 | 0.060 |
Why?
|
| cdc25 Phosphatases | 1 | 2005 | 62 | 0.060 |
Why?
|
| Cholesterol | 2 | 2006 | 2917 | 0.060 |
Why?
|
| Antigen-Antibody Reactions | 1 | 2005 | 363 | 0.060 |
Why?
|
| International Cooperation | 1 | 2012 | 1420 | 0.060 |
Why?
|
| Stimulation, Chemical | 1 | 2005 | 326 | 0.060 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2005 | 370 | 0.060 |
Why?
|
| Retrospective Studies | 8 | 2024 | 77449 | 0.060 |
Why?
|
| G2 Phase | 1 | 2005 | 139 | 0.060 |
Why?
|
| Drug Combinations | 2 | 2011 | 1959 | 0.060 |
Why?
|
| Conflict of Interest | 1 | 2010 | 544 | 0.060 |
Why?
|
| Retinoblastoma-Like Protein p130 | 1 | 2004 | 76 | 0.060 |
Why?
|
| Autoantigens | 1 | 2009 | 892 | 0.060 |
Why?
|
| Angiopoietin-2 | 1 | 2006 | 173 | 0.060 |
Why?
|
| Immune System | 2 | 2008 | 805 | 0.060 |
Why?
|
| Bone Regeneration | 1 | 2008 | 427 | 0.060 |
Why?
|
| Staurosporine | 1 | 2005 | 251 | 0.060 |
Why?
|
| Cytoskeletal Proteins | 3 | 2009 | 1364 | 0.060 |
Why?
|
| Daunorubicin | 1 | 2004 | 158 | 0.060 |
Why?
|
| Antibodies, Neoplasm | 1 | 2006 | 286 | 0.060 |
Why?
|
| Zebrafish | 1 | 2016 | 2994 | 0.060 |
Why?
|
| Bone Marrow Purging | 1 | 2004 | 109 | 0.060 |
Why?
|
| Neoplasm Metastasis | 3 | 2015 | 4851 | 0.060 |
Why?
|
| Precipitin Tests | 2 | 2003 | 829 | 0.060 |
Why?
|
| GABA-A Receptor Antagonists | 1 | 2004 | 62 | 0.060 |
Why?
|
| Colonic Neoplasms | 2 | 2009 | 2541 | 0.060 |
Why?
|
| Thromboembolism | 1 | 2011 | 986 | 0.060 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2010 | 986 | 0.060 |
Why?
|
| Specimen Handling | 1 | 2009 | 694 | 0.060 |
Why?
|
| Chickens | 1 | 2006 | 865 | 0.060 |
Why?
|
| Osteogenesis | 2 | 2009 | 1299 | 0.060 |
Why?
|
| Contactins | 1 | 2003 | 21 | 0.060 |
Why?
|
| CDC2 Protein Kinase | 1 | 2005 | 220 | 0.060 |
Why?
|
| Quinolines | 1 | 2009 | 732 | 0.060 |
Why?
|
| Stereoisomerism | 1 | 2005 | 624 | 0.060 |
Why?
|
| Barrett Esophagus | 1 | 2008 | 494 | 0.060 |
Why?
|
| Caspase 7 | 1 | 2003 | 56 | 0.060 |
Why?
|
| Homeostasis | 2 | 2012 | 3340 | 0.060 |
Why?
|
| Molecular Biology | 1 | 2008 | 596 | 0.060 |
Why?
|
| CA-125 Antigen | 1 | 2006 | 286 | 0.060 |
Why?
|
| Tyrphostins | 1 | 2003 | 67 | 0.060 |
Why?
|
| Antioxidants | 3 | 2015 | 1663 | 0.060 |
Why?
|
| Comorbidity | 1 | 2018 | 10388 | 0.060 |
Why?
|
| Phosphoric Acids | 1 | 2003 | 24 | 0.060 |
Why?
|
| Chi-Square Distribution | 2 | 2008 | 3508 | 0.060 |
Why?
|
| Cytokine Receptor gp130 | 1 | 2003 | 66 | 0.060 |
Why?
|
| Algorithms | 3 | 2012 | 13881 | 0.060 |
Why?
|
| Interleukin-17 | 1 | 2010 | 899 | 0.060 |
Why?
|
| Hyperplasia | 1 | 2007 | 1185 | 0.060 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2005 | 643 | 0.060 |
Why?
|
| Disclosure | 1 | 2010 | 736 | 0.060 |
Why?
|
| Mastocytosis | 1 | 2006 | 160 | 0.060 |
Why?
|
| Isoantibodies | 1 | 2008 | 679 | 0.060 |
Why?
|
| Cytochromes c | 1 | 2004 | 180 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2016 | 3589 | 0.060 |
Why?
|
| Energy Metabolism | 1 | 2015 | 2899 | 0.060 |
Why?
|
| Adenosine Triphosphate | 2 | 2012 | 2025 | 0.060 |
Why?
|
| Microarray Analysis | 1 | 2006 | 767 | 0.060 |
Why?
|
| Drug Industry | 1 | 2010 | 746 | 0.060 |
Why?
|
| Serum Albumin, Bovine | 1 | 2004 | 324 | 0.060 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2003 | 112 | 0.060 |
Why?
|
| Biological Transport | 2 | 2013 | 2118 | 0.060 |
Why?
|
| Tetrazolium Salts | 1 | 2003 | 96 | 0.060 |
Why?
|
| Interleukin-12 | 2 | 2005 | 579 | 0.060 |
Why?
|
| Europe | 2 | 2020 | 3339 | 0.060 |
Why?
|
| Immunomagnetic Separation | 1 | 2003 | 80 | 0.060 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2005 | 434 | 0.060 |
Why?
|
| Microfilament Proteins | 1 | 2009 | 1152 | 0.060 |
Why?
|
| Cell Line, Transformed | 1 | 2005 | 898 | 0.060 |
Why?
|
| Paraproteins | 2 | 2018 | 39 | 0.060 |
Why?
|
| Receptor Cross-Talk | 1 | 2003 | 119 | 0.060 |
Why?
|
| Mutation, Missense | 4 | 2018 | 2564 | 0.060 |
Why?
|
| Phylogeny | 2 | 2022 | 2803 | 0.060 |
Why?
|
| Genes, Immunoglobulin | 1 | 2004 | 291 | 0.060 |
Why?
|
| Transcription Factor AP-1 | 1 | 2005 | 317 | 0.060 |
Why?
|
| Sphingosine | 1 | 2005 | 307 | 0.060 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2005 | 573 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 3158 | 0.060 |
Why?
|
| Phosphotyrosine | 1 | 2004 | 457 | 0.060 |
Why?
|
| Tyrosine | 2 | 2004 | 1461 | 0.060 |
Why?
|
| Cyclin D1 | 1 | 2005 | 463 | 0.060 |
Why?
|
| Risk Reduction Behavior | 1 | 2010 | 1125 | 0.060 |
Why?
|
| Models, Immunological | 1 | 2005 | 527 | 0.060 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2003 | 279 | 0.060 |
Why?
|
| Melanoma | 1 | 2021 | 5510 | 0.050 |
Why?
|
| Etoposide | 2 | 2021 | 641 | 0.050 |
Why?
|
| Interferons | 2 | 2006 | 706 | 0.050 |
Why?
|
| Electroporation | 1 | 2004 | 251 | 0.050 |
Why?
|
| Canada | 2 | 2020 | 2065 | 0.050 |
Why?
|
| Phagocytosis | 2 | 2012 | 1539 | 0.050 |
Why?
|
| NFATC Transcription Factors | 1 | 2005 | 381 | 0.050 |
Why?
|
| Hypergammaglobulinemia | 2 | 2016 | 74 | 0.050 |
Why?
|
| Isoquinolines | 1 | 2004 | 367 | 0.050 |
Why?
|
| Oxazoles | 1 | 2004 | 189 | 0.050 |
Why?
|
| Positron-Emission Tomography | 4 | 2015 | 6234 | 0.050 |
Why?
|
| HeLa Cells | 4 | 2013 | 3128 | 0.050 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2023 | 154 | 0.050 |
Why?
|
| Organic Anion Transporters, Sodium-Independent | 1 | 2022 | 24 | 0.050 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2003 | 318 | 0.050 |
Why?
|
| Membrane Microdomains | 1 | 2003 | 203 | 0.050 |
Why?
|
| Tissue Extracts | 1 | 2002 | 135 | 0.050 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2002 | 117 | 0.050 |
Why?
|
| Phosphoserine | 1 | 2002 | 206 | 0.050 |
Why?
|
| Drug Therapy | 1 | 2005 | 497 | 0.050 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2005 | 233 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2005 | 595 | 0.050 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2002 | 65 | 0.050 |
Why?
|
| Mitoxantrone | 1 | 2002 | 152 | 0.050 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2002 | 87 | 0.050 |
Why?
|
| Acetylcysteine | 1 | 2003 | 272 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 35421 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2002 | 118 | 0.050 |
Why?
|
| Chromosomes, Human | 2 | 2019 | 457 | 0.050 |
Why?
|
| bcl-Associated Death Protein | 1 | 2002 | 107 | 0.050 |
Why?
|
| Interleukin-15 | 1 | 2023 | 184 | 0.050 |
Why?
|
| Blood Banks | 1 | 2002 | 111 | 0.050 |
Why?
|
| Diarrhea | 2 | 2012 | 1348 | 0.050 |
Why?
|
| Melanoma, Experimental | 2 | 2018 | 561 | 0.050 |
Why?
|
| Integrin alpha4beta1 | 2 | 2014 | 121 | 0.050 |
Why?
|
| Enzyme Induction | 1 | 2002 | 475 | 0.050 |
Why?
|
| Solubility | 2 | 2014 | 1085 | 0.050 |
Why?
|
| Protein Kinase C-alpha | 1 | 2001 | 112 | 0.050 |
Why?
|
| Receptors, Interferon | 1 | 2002 | 115 | 0.050 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2002 | 336 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2006 | 1730 | 0.050 |
Why?
|
| Vaccines, Subunit | 2 | 2012 | 168 | 0.050 |
Why?
|
| Diseases in Twins | 1 | 2003 | 449 | 0.050 |
Why?
|
| Microscopy, Video | 1 | 2001 | 245 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2008 | 1366 | 0.050 |
Why?
|
| Palatine Tonsil | 1 | 2002 | 193 | 0.050 |
Why?
|
| Retinoblastoma-Binding Protein 2 | 1 | 2021 | 31 | 0.050 |
Why?
|
| Consensus Development Conferences as Topic | 2 | 2014 | 170 | 0.050 |
Why?
|
| Cohort Studies | 9 | 2017 | 40561 | 0.050 |
Why?
|
| Porphyrins | 1 | 2003 | 348 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2014 | 3528 | 0.050 |
Why?
|
| Base Sequence | 3 | 2022 | 12797 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2021 | 66 | 0.050 |
Why?
|
| Cell Degranulation | 2 | 2012 | 287 | 0.050 |
Why?
|
| Myeloablative Agonists | 2 | 2015 | 218 | 0.050 |
Why?
|
| Fluorescence | 1 | 2003 | 751 | 0.050 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2002 | 272 | 0.050 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2003 | 433 | 0.050 |
Why?
|
| Gene Silencing | 2 | 2018 | 1538 | 0.050 |
Why?
|
| Genes, cdc | 1 | 2021 | 116 | 0.050 |
Why?
|
| Immunoglobulin Light Chains | 2 | 2012 | 277 | 0.050 |
Why?
|
| Subcellular Fractions | 1 | 2001 | 547 | 0.050 |
Why?
|
| Necrosis | 1 | 2005 | 1643 | 0.050 |
Why?
|
| Herpesviridae Infections | 1 | 2002 | 277 | 0.050 |
Why?
|
| Risk Assessment | 5 | 2023 | 23338 | 0.050 |
Why?
|
| Amides | 1 | 2003 | 459 | 0.050 |
Why?
|
| Lectins | 1 | 2003 | 513 | 0.050 |
Why?
|
| Odds Ratio | 4 | 2020 | 9849 | 0.050 |
Why?
|
| Venous Thrombosis | 2 | 2008 | 1239 | 0.050 |
Why?
|
| Janus Kinase 2 | 2 | 2017 | 528 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 1801 | 0.050 |
Why?
|
| Coloring Agents | 1 | 2003 | 566 | 0.050 |
Why?
|
| Reproducibility of Results | 4 | 2020 | 19905 | 0.050 |
Why?
|
| Adolescent | 4 | 2022 | 85781 | 0.050 |
Why?
|
| Blood Donors | 1 | 2002 | 355 | 0.050 |
Why?
|
| DNA Methylation | 2 | 2016 | 4286 | 0.050 |
Why?
|
| Transplantation, Isogeneic | 2 | 2012 | 257 | 0.050 |
Why?
|
| Single-Cell Analysis | 2 | 2021 | 2183 | 0.050 |
Why?
|
| Complement System Proteins | 1 | 2003 | 795 | 0.050 |
Why?
|
| Genes, Dominant | 1 | 2003 | 880 | 0.050 |
Why?
|
| Exocytosis | 1 | 2001 | 353 | 0.050 |
Why?
|
| Mice, Mutant Strains | 1 | 2003 | 1866 | 0.050 |
Why?
|
| Extracellular Matrix | 1 | 2007 | 1741 | 0.040 |
Why?
|
| Burkitt Lymphoma | 1 | 2002 | 327 | 0.040 |
Why?
|
| Models, Molecular | 3 | 2017 | 5456 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2012 | 2958 | 0.040 |
Why?
|
| Triazoles | 2 | 2018 | 911 | 0.040 |
Why?
|
| Nephritis | 1 | 2020 | 159 | 0.040 |
Why?
|
| Cytosol | 1 | 2003 | 901 | 0.040 |
Why?
|
| Models, Chemical | 1 | 2002 | 626 | 0.040 |
Why?
|
| HEK293 Cells | 3 | 2014 | 4204 | 0.040 |
Why?
|
| Inheritance Patterns | 1 | 2022 | 340 | 0.040 |
Why?
|
| Phenotype | 4 | 2020 | 16365 | 0.040 |
Why?
|
| Influenza A virus | 1 | 2003 | 456 | 0.040 |
Why?
|
| Genetics | 1 | 2020 | 112 | 0.040 |
Why?
|
| Amino Acid Substitution | 2 | 2015 | 1791 | 0.040 |
Why?
|
| Azithromycin | 1 | 2020 | 196 | 0.040 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2002 | 369 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2020 | 426 | 0.040 |
Why?
|
| Transcription Factor DP1 | 1 | 2018 | 141 | 0.040 |
Why?
|
| Serine | 1 | 2003 | 826 | 0.040 |
Why?
|
| Oncogene Proteins | 1 | 2003 | 749 | 0.040 |
Why?
|
| INDEL Mutation | 1 | 2020 | 279 | 0.040 |
Why?
|
| Biomarkers, Pharmacological | 2 | 2010 | 162 | 0.040 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2020 | 298 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2014 | 1654 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2020 | 417 | 0.040 |
Why?
|
| RNA Editing | 1 | 2020 | 148 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2020 | 354 | 0.040 |
Why?
|
| Mast Cells | 1 | 2006 | 1544 | 0.040 |
Why?
|
| Genetic Loci | 2 | 2020 | 2575 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2002 | 1547 | 0.040 |
Why?
|
| E2F1 Transcription Factor | 1 | 2018 | 190 | 0.040 |
Why?
|
| International Agencies | 1 | 2019 | 240 | 0.040 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2022 | 584 | 0.040 |
Why?
|
| Cell Separation | 1 | 2004 | 1751 | 0.040 |
Why?
|
| Estrogens | 1 | 2005 | 1566 | 0.040 |
Why?
|
| Genetic Variation | 2 | 2016 | 6544 | 0.040 |
Why?
|
| Osteoporosis | 1 | 2008 | 1580 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2002 | 776 | 0.040 |
Why?
|
| Leucine | 2 | 2013 | 561 | 0.040 |
Why?
|
| Dioxygenases | 1 | 2020 | 316 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2022 | 775 | 0.040 |
Why?
|
| Chromosome Disorders | 1 | 2021 | 514 | 0.040 |
Why?
|
| Crystallography, X-Ray | 2 | 2013 | 2011 | 0.040 |
Why?
|
| Cytidine Deaminase | 1 | 2020 | 252 | 0.040 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2002 | 849 | 0.040 |
Why?
|
| Asia | 1 | 2019 | 610 | 0.040 |
Why?
|
| Rad51 Recombinase | 1 | 2018 | 189 | 0.040 |
Why?
|
| Androgens | 1 | 2005 | 1281 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2003 | 1041 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2003 | 847 | 0.040 |
Why?
|
| Constipation | 1 | 2002 | 546 | 0.040 |
Why?
|
| Carcinoma | 1 | 2009 | 2375 | 0.040 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2022 | 581 | 0.040 |
Why?
|
| Tissue Distribution | 2 | 2012 | 2327 | 0.040 |
Why?
|
| Steroids | 1 | 2003 | 930 | 0.040 |
Why?
|
| Neutrophils | 1 | 2010 | 3719 | 0.040 |
Why?
|
| Multigene Family | 1 | 2021 | 1102 | 0.040 |
Why?
|
| Carboplatin | 1 | 2020 | 801 | 0.040 |
Why?
|
| GPI-Linked Proteins | 2 | 2012 | 434 | 0.040 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 15540 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2002 | 1539 | 0.040 |
Why?
|
| Caregivers | 2 | 2022 | 2094 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2003 | 1534 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2022 | 713 | 0.040 |
Why?
|
| Radiopharmaceuticals | 2 | 2017 | 2645 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2012 | 1799 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2011 | 4234 | 0.040 |
Why?
|
| Mitochondrial Diseases | 1 | 2020 | 320 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2020 | 403 | 0.040 |
Why?
|
| Bone Transplantation | 3 | 2007 | 907 | 0.040 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 412 | 0.040 |
Why?
|
| RNA Polymerase II | 1 | 2021 | 551 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 14722 | 0.040 |
Why?
|
| Tissue Donors | 2 | 2005 | 2240 | 0.040 |
Why?
|
| World Health Organization | 1 | 2022 | 1318 | 0.040 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2016 | 25 | 0.040 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2022 | 736 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2012 | 4253 | 0.030 |
Why?
|
| Membrane Transport Proteins | 1 | 2022 | 1028 | 0.030 |
Why?
|
| Transduction, Genetic | 2 | 2012 | 913 | 0.030 |
Why?
|
| North America | 1 | 2019 | 1249 | 0.030 |
Why?
|
| Hydrogels | 1 | 2021 | 724 | 0.030 |
Why?
|
| Fetal Blood | 1 | 2002 | 1318 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2018 | 711 | 0.030 |
Why?
|
| Blood Coagulation | 2 | 2012 | 1127 | 0.030 |
Why?
|
| Loss of Heterozygosity | 1 | 2018 | 684 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2006 | 3760 | 0.030 |
Why?
|
| Young Adult | 5 | 2020 | 56430 | 0.030 |
Why?
|
| Receptor, erbB-2 | 1 | 2005 | 2416 | 0.030 |
Why?
|
| Amino Acid Sequence | 3 | 2013 | 13815 | 0.030 |
Why?
|
| DNA, Mitochondrial | 1 | 2020 | 817 | 0.030 |
Why?
|
| Polymers | 1 | 2023 | 1621 | 0.030 |
Why?
|
| Genetic Vectors | 2 | 2016 | 3420 | 0.030 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2015 | 107 | 0.030 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2013 | 496 | 0.030 |
Why?
|
| Allosteric Regulation | 1 | 2017 | 408 | 0.030 |
Why?
|
| Trypsin | 1 | 2016 | 511 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2006 | 2921 | 0.030 |
Why?
|
| Catalytic Domain | 1 | 2017 | 698 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2002 | 1613 | 0.030 |
Why?
|
| Minority Groups | 1 | 2002 | 1223 | 0.030 |
Why?
|
| bcl-X Protein | 1 | 2016 | 411 | 0.030 |
Why?
|
| Pain | 1 | 2010 | 4986 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2013 | 805 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2009 | 15076 | 0.030 |
Why?
|
| Lymphotoxin-beta | 1 | 2014 | 12 | 0.030 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2020 | 770 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2015 | 424 | 0.030 |
Why?
|
| France | 1 | 2015 | 517 | 0.030 |
Why?
|
| Drug Administration Routes | 1 | 2014 | 153 | 0.030 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2015 | 180 | 0.030 |
Why?
|
| Chromosomal Instability | 1 | 2015 | 184 | 0.030 |
Why?
|
| Kidney | 1 | 2010 | 7186 | 0.030 |
Why?
|
| China | 1 | 2020 | 2248 | 0.030 |
Why?
|
| Matched-Pair Analysis | 1 | 2014 | 288 | 0.030 |
Why?
|
| Point Mutation | 1 | 2019 | 1623 | 0.030 |
Why?
|
| Ovarian Neoplasms | 2 | 2011 | 4838 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2018 | 594 | 0.030 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2014 | 140 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2022 | 2019 | 0.030 |
Why?
|
| Rhodamine 123 | 1 | 2013 | 38 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2002 | 2902 | 0.030 |
Why?
|
| Phase Transition | 1 | 2013 | 74 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2018 | 970 | 0.030 |
Why?
|
| rhoB GTP-Binding Protein | 1 | 2013 | 16 | 0.030 |
Why?
|
| Adenocarcinoma | 2 | 2008 | 6364 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 12245 | 0.030 |
Why?
|
| Germany | 1 | 2015 | 862 | 0.030 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 2 | 2004 | 49 | 0.030 |
Why?
|
| Therapies, Investigational | 1 | 2014 | 112 | 0.030 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2013 | 78 | 0.030 |
Why?
|
| Palliative Care | 2 | 2014 | 3493 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 3 | 2011 | 6386 | 0.030 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2013 | 57 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2006 | 3327 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 2009 | 4256 | 0.030 |
Why?
|
| Early Detection of Cancer | 2 | 2020 | 3086 | 0.030 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2013 | 91 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2021 | 2751 | 0.030 |
Why?
|
| SEER Program | 1 | 2018 | 1508 | 0.030 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 2012 | 91 | 0.030 |
Why?
|
| Solutions | 1 | 2013 | 426 | 0.030 |
Why?
|
| Placebos | 1 | 2017 | 1676 | 0.030 |
Why?
|
| Evidence-Based Medicine | 3 | 2014 | 3610 | 0.030 |
Why?
|
| Densitometry | 1 | 2012 | 156 | 0.030 |
Why?
|
| Buffers | 1 | 2012 | 147 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2014 | 6365 | 0.030 |
Why?
|
| Sulfones | 1 | 2015 | 437 | 0.030 |
Why?
|
| Bone Marrow Examination | 1 | 2012 | 157 | 0.030 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2002 | 1352 | 0.030 |
Why?
|
| Genes, MHC Class II | 1 | 2013 | 457 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2013 | 220 | 0.030 |
Why?
|
| Antimetabolites | 1 | 2012 | 125 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 2013 | 387 | 0.030 |
Why?
|
| Rats, Inbred Lew | 1 | 2013 | 1162 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2002 | 1622 | 0.030 |
Why?
|
| Quinoxalines | 1 | 2014 | 290 | 0.030 |
Why?
|
| Sulfoxides | 1 | 2011 | 48 | 0.030 |
Why?
|
| Vaccines, DNA | 1 | 2013 | 305 | 0.030 |
Why?
|
| Validation Studies as Topic | 1 | 2012 | 159 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2012 | 380 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 2013 | 537 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2018 | 1301 | 0.020 |
Why?
|
| Spain | 1 | 2012 | 465 | 0.020 |
Why?
|
| Crystallization | 1 | 2012 | 524 | 0.020 |
Why?
|
| Clinical Protocols | 2 | 2009 | 1462 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2019 | 2309 | 0.020 |
Why?
|
| Luciferases | 1 | 2013 | 733 | 0.020 |
Why?
|
| Tissue Engineering | 1 | 2021 | 1880 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 15165 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2018 | 1783 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 25043 | 0.020 |
Why?
|
| Cell Compartmentation | 1 | 2012 | 402 | 0.020 |
Why?
|
| 3T3 Cells | 2 | 2003 | 1101 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2014 | 893 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2019 | 1170 | 0.020 |
Why?
|
| Proline | 1 | 2013 | 458 | 0.020 |
Why?
|
| Chlorambucil | 1 | 2010 | 43 | 0.020 |
Why?
|
| Cladribine | 1 | 2010 | 34 | 0.020 |
Why?
|
| Homeodomain Proteins | 2 | 2011 | 2421 | 0.020 |
Why?
|
| Exercise | 1 | 2007 | 5615 | 0.020 |
Why?
|
| X-Ray Microtomography | 1 | 2013 | 428 | 0.020 |
Why?
|
| Binding Sites, Antibody | 1 | 2010 | 349 | 0.020 |
Why?
|
| Benchmarking | 1 | 2017 | 1042 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2015 | 599 | 0.020 |
Why?
|
| Ribonucleases | 1 | 2011 | 287 | 0.020 |
Why?
|
| Twins | 1 | 2012 | 339 | 0.020 |
Why?
|
| Particle Size | 1 | 2014 | 1642 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2020 | 14557 | 0.020 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2010 | 69 | 0.020 |
Why?
|
| Protein Inhibitors of Activated STAT | 1 | 2009 | 33 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2002 | 3461 | 0.020 |
Why?
|
| Immediate-Early Proteins | 1 | 2013 | 453 | 0.020 |
Why?
|
| Integrins | 1 | 2014 | 846 | 0.020 |
Why?
|
| Registries | 2 | 2020 | 8089 | 0.020 |
Why?
|
| Prednisolone | 1 | 2011 | 334 | 0.020 |
Why?
|
| Financing, Government | 1 | 2013 | 468 | 0.020 |
Why?
|
| Lymphocyte Depletion | 1 | 2012 | 608 | 0.020 |
Why?
|
| Smad2 Protein | 1 | 2010 | 156 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2012 | 915 | 0.020 |
Why?
|
| Linear Models | 1 | 2020 | 5952 | 0.020 |
Why?
|
| DNA Primers | 1 | 2014 | 2892 | 0.020 |
Why?
|
| Small Ubiquitin-Related Modifier Proteins | 1 | 2009 | 72 | 0.020 |
Why?
|
| Permeability | 1 | 2011 | 738 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2007 | 12720 | 0.020 |
Why?
|
| Calcium | 1 | 2002 | 5756 | 0.020 |
Why?
|
| Ribosomal Protein S6 | 1 | 2009 | 70 | 0.020 |
Why?
|
| Antibodies, Protozoan | 1 | 2010 | 253 | 0.020 |
Why?
|
| Benzodioxoles | 1 | 2009 | 69 | 0.020 |
Why?
|
| Dyspnea | 1 | 2017 | 1303 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2010 | 677 | 0.020 |
Why?
|
| Research Support as Topic | 1 | 2013 | 705 | 0.020 |
Why?
|
| Cricetulus | 1 | 2010 | 816 | 0.020 |
Why?
|
| Immunization | 1 | 2013 | 1256 | 0.020 |
Why?
|
| Periodontal Pocket | 1 | 2009 | 166 | 0.020 |
Why?
|
| Butadienes | 1 | 2008 | 110 | 0.020 |
Why?
|
| Dogs | 1 | 2013 | 3912 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2018 | 1786 | 0.020 |
Why?
|
| Pregnancy | 2 | 2008 | 29144 | 0.020 |
Why?
|
| Plasmids | 1 | 2014 | 2307 | 0.020 |
Why?
|
| Antigens, Protozoan | 1 | 2010 | 322 | 0.020 |
Why?
|
| Microdissection | 1 | 2008 | 152 | 0.020 |
Why?
|
| Antibody Formation | 2 | 2003 | 1402 | 0.020 |
Why?
|
| CHO Cells | 1 | 2010 | 1406 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2023 | 9146 | 0.020 |
Why?
|
| Polyneuropathies | 1 | 2009 | 137 | 0.020 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2011 | 436 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2009 | 862 | 0.020 |
Why?
|
| Cross-Priming | 1 | 2008 | 82 | 0.020 |
Why?
|
| Tooth Extraction | 1 | 2009 | 222 | 0.020 |
Why?
|
| Dromaiidae | 1 | 2007 | 7 | 0.020 |
Why?
|
| Perylene | 1 | 2007 | 16 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2011 | 810 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2011 | 560 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2015 | 1357 | 0.020 |
Why?
|
| Glucuronidase | 1 | 2009 | 207 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2012 | 2557 | 0.020 |
Why?
|
| Albumins | 1 | 2010 | 569 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 1142 | 0.020 |
Why?
|
| Temperature | 1 | 2013 | 2206 | 0.020 |
Why?
|
| Cricetinae | 1 | 2010 | 2472 | 0.020 |
Why?
|
| Glyoxal | 1 | 2006 | 11 | 0.020 |
Why?
|
| Receptors, Laminin | 1 | 2006 | 26 | 0.020 |
Why?
|
| Tetanus Toxoid | 1 | 2007 | 193 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2022 | 4245 | 0.020 |
Why?
|
| Femur | 1 | 2013 | 1297 | 0.020 |
Why?
|
| Time | 1 | 2008 | 542 | 0.020 |
Why?
|
| Virus Activation | 1 | 2008 | 319 | 0.020 |
Why?
|
| Binding Sites | 1 | 2015 | 6114 | 0.020 |
Why?
|
| Thanatophoric Dysplasia | 1 | 2005 | 5 | 0.020 |
Why?
|
| Calpain | 1 | 2007 | 150 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2010 | 607 | 0.020 |
Why?
|
| Diploidy | 1 | 2006 | 138 | 0.020 |
Why?
|
| Carmustine | 1 | 2006 | 137 | 0.020 |
Why?
|
| Tissue Scaffolds | 1 | 2013 | 956 | 0.020 |
Why?
|
| Antigens, CD1 | 1 | 2008 | 437 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2002 | 4262 | 0.020 |
Why?
|
| Denmark | 1 | 2008 | 738 | 0.020 |
Why?
|
| Hybrid Cells | 1 | 2005 | 441 | 0.020 |
Why?
|
| Fourier Analysis | 1 | 2006 | 447 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2007 | 743 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2007 | 876 | 0.020 |
Why?
|
| Collagen | 1 | 2013 | 2689 | 0.020 |
Why?
|
| Receptors, CCR7 | 1 | 2005 | 108 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2013 | 1917 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 2006 | 449 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2010 | 1057 | 0.020 |
Why?
|
| Computational Biology | 1 | 2017 | 3521 | 0.020 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2008 | 386 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2014 | 1940 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2021 | 4468 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2012 | 1222 | 0.020 |
Why?
|
| Fetal Tissue Transplantation | 1 | 2005 | 139 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 7181 | 0.020 |
Why?
|
| Tea | 1 | 2006 | 275 | 0.020 |
Why?
|
| Catalysis | 1 | 2006 | 761 | 0.020 |
Why?
|
| Leukapheresis | 1 | 2004 | 131 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2012 | 20129 | 0.020 |
Why?
|
| Antigens, CD19 | 1 | 2007 | 380 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 3846 | 0.010 |
Why?
|
| Phytotherapy | 1 | 2006 | 298 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2015 | 3086 | 0.010 |
Why?
|
| Lasers | 1 | 2008 | 952 | 0.010 |
Why?
|
| Erythropoietin | 1 | 2008 | 726 | 0.010 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2004 | 185 | 0.010 |
Why?
|
| Gene Amplification | 1 | 2008 | 1063 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2014 | 2266 | 0.010 |
Why?
|
| Logistic Models | 2 | 2009 | 13408 | 0.010 |
Why?
|
| Tunicamycin | 1 | 2003 | 112 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2011 | 2126 | 0.010 |
Why?
|
| Aorta, Thoracic | 1 | 2010 | 1082 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2015 | 3474 | 0.010 |
Why?
|
| Arginine | 1 | 2007 | 944 | 0.010 |
Why?
|
| Codon | 1 | 2005 | 611 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 2886 | 0.010 |
Why?
|
| Quinazolines | 1 | 2009 | 1356 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 2004 | 390 | 0.010 |
Why?
|
| Deoxyribonuclease I | 1 | 2003 | 229 | 0.010 |
Why?
|
| Depression | 1 | 2022 | 7766 | 0.010 |
Why?
|
| Inflammation | 1 | 2002 | 10638 | 0.010 |
Why?
|
| Glomerular Filtration Rate | 1 | 2010 | 2170 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2008 | 2297 | 0.010 |
Why?
|
| Physician's Role | 1 | 2010 | 943 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 2005 | 684 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2018 | 4371 | 0.010 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2011 | 1519 | 0.010 |
Why?
|
| Plasmapheresis | 1 | 2003 | 211 | 0.010 |
Why?
|
| Cell Size | 1 | 2004 | 643 | 0.010 |
Why?
|
| Haplotypes | 1 | 2009 | 2779 | 0.010 |
Why?
|
| Immunodominant Epitopes | 1 | 2003 | 267 | 0.010 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2002 | 112 | 0.010 |
Why?
|
| Age Distribution | 1 | 2008 | 2902 | 0.010 |
Why?
|
| Receptors, Chemokine | 1 | 2005 | 669 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 2007 | 1185 | 0.010 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2002 | 114 | 0.010 |
Why?
|
| Cell Transformation, Viral | 1 | 2003 | 565 | 0.010 |
Why?
|
| Splenectomy | 1 | 2003 | 395 | 0.010 |
Why?
|
| Antigens | 1 | 2007 | 1466 | 0.010 |
Why?
|
| Receptors, Calcium-Sensing | 1 | 2002 | 315 | 0.010 |
Why?
|
| Glutathione | 1 | 2004 | 589 | 0.010 |
Why?
|
| Age of Onset | 1 | 2008 | 3271 | 0.010 |
Why?
|
| G-Quadruplexes | 1 | 2003 | 162 | 0.010 |
Why?
|
| Glioma | 1 | 2016 | 3401 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2016 | 5102 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2015 | 2734 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 13989 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 2002 | 221 | 0.010 |
Why?
|
| Hydroxyurea | 1 | 2002 | 290 | 0.010 |
Why?
|
| Gene Library | 1 | 2003 | 1074 | 0.010 |
Why?
|
| Body Height | 1 | 2007 | 1577 | 0.010 |
Why?
|
| Information Storage and Retrieval | 1 | 2006 | 824 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2006 | 1770 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 2003 | 927 | 0.010 |
Why?
|
| Venous Thromboembolism | 1 | 2012 | 1671 | 0.010 |
Why?
|
| Cytarabine | 1 | 2002 | 692 | 0.010 |
Why?
|
| Medicare | 1 | 2018 | 6566 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2003 | 1147 | 0.010 |
Why?
|
| Leukocytes | 1 | 2008 | 2043 | 0.010 |
Why?
|
| Myeloproliferative Disorders | 1 | 2005 | 606 | 0.010 |
Why?
|
| Transplantation Chimera | 1 | 2002 | 612 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2005 | 2559 | 0.010 |
Why?
|
| Actins | 1 | 2007 | 2121 | 0.010 |
Why?
|
| Insulin | 1 | 2013 | 6580 | 0.010 |
Why?
|
| Cultural Diversity | 1 | 2002 | 359 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2004 | 1586 | 0.010 |
Why?
|
| Skin Diseases | 1 | 2007 | 1065 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 13102 | 0.010 |
Why?
|
| Graft Survival | 1 | 2007 | 3737 | 0.010 |
Why?
|
| Bone Density | 1 | 2009 | 3468 | 0.010 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2004 | 1581 | 0.010 |
Why?
|
| Drug Monitoring | 1 | 2002 | 956 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 4982 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2008 | 3690 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2008 | 2376 | 0.010 |
Why?
|
| Viral Proteins | 1 | 2002 | 1900 | 0.010 |
Why?
|
| Mass Screening | 1 | 2010 | 5255 | 0.010 |
Why?
|
| Sex Factors | 1 | 2008 | 10397 | 0.010 |
Why?
|
| Heart Failure | 1 | 2017 | 10900 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2006 | 6196 | 0.010 |
Why?
|
| Child | 2 | 2011 | 77709 | 0.010 |
Why?
|
| Aging | 1 | 2007 | 8664 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 2002 | 25625 | 0.000 |
Why?
|